178 results on '"Kinase activity"'
Search Results
2. Effect of various procedures on nucleoside phosphate kinase activity of normal and tumor cells
- Author
-
Nyazanov, E
- Published
- 1986
3. Pathological glycogenesis through glycogen synthase 1 and suppression of excessive AMP kinase activity in myeloid leukemia cells.
- Author
-
Bhanot, H, Reddy, M M, Nonami, A, Weisberg, E L, Bonal, D, Kirschmeier, P T, Salgia, S, Podar, K, Galinsky, I, Chowdary, T K, Neuberg, D, Tonon, G, Stone, R M, Asara, J, Griffin, J D, and Sattler, M
- Subjects
MYELOID leukemia ,GLUCOSE metabolism ,GLYCOGEN synthases ,LEUKEMIA ,GENOMICS ,ANIMALS ,APOPTOSIS ,BIOCHEMISTRY ,CELL physiology ,EPITHELIAL cells ,FLOW cytometry ,GLYCOGEN ,GLYCOLYSIS ,MICE ,PHOSPHORYLATION ,PHOSPHOTRANSFERASES ,POLYMERASE chain reaction ,PROGNOSIS ,RNA ,SURVIVAL ,TRANSFERASES ,CASE-control method ,REVERSE transcriptase polymerase chain reaction ,CANCER cell culture - Abstract
The rapid proliferation of myeloid leukemia cells is highly dependent on increased glucose metabolism. Through an unbiased metabolomics analysis of leukemia cells, we found that the glycogenic precursor UDP-D-glucose is pervasively upregulated, despite low glycogen levels. Targeting the rate-limiting glycogen synthase 1 (GYS1) not only decreased glycolytic flux but also increased activation of the glycogen-responsive AMP kinase (AMPK), leading to significant growth suppression. Further, genetic and pharmacological hyper-activation of AMPK was sufficient to induce the changes observed with GYS1 targeting. Cancer genomics data also indicate that elevated levels of the glycogenic enzymes GYS1/2 or GBE1 (glycogen branching enzyme 1) are associated with poor survival in AML. These results suggest a novel mechanism whereby leukemic cells sustain aberrant proliferation by suppressing excess AMPK activity through elevated glycogenic flux and provide a therapeutic entry point for targeting leukemia cell metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
4. The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.
- Author
-
Winkler, Aaron, Sun, Weiyong, De, Saurav, Jiao, Aiping, Sharif, M. Nusrat, Symanowicz, Peter T., Athale, Shruti, Shin, Julia H., Wang, Ju, Jacobson, Bruce A., Ramsey, Simeon J., Dower, Ken, Andreyeva, Tatyana, Liu, Heng, Hegen, Martin, Homer, Bruce L., Brodfuehrer, Joanne, Tilley, Mera, Gilbert, Steven A., and Danto, Spencer I.
- Subjects
DRUG therapy for rheumatism ,INFLAMMATION prevention ,IN vitro studies ,BIOLOGICAL models ,AUTOANTIBODIES ,CLINICAL drug trials ,IN vivo studies ,SEQUENCE analysis ,ANTI-inflammatory agents ,ANIMAL experimentation ,INTERLEUKIN-1 ,RNA ,RANDOMIZED controlled trials ,GENE expression ,TREATMENT effectiveness ,TRANSFERASES ,RHEUMATOID arthritis ,RHEUMATISM ,DRUG development ,SYSTEMIC lupus erythematosus ,MICE ,TOLL-like receptors ,LIGANDS (Biochemistry) ,PHARMACODYNAMICS ,CHEMICAL inhibitors - Abstract
Objective: To investigate the role of PF‐06650833, a highly potent and selective small‐molecule inhibitor of interleukin‐1–associated kinase 4 (IRAK4), in autoimmune pathophysiology in vitro, in vivo, and in the clinical setting. Methods: Rheumatoid arthritis (RA) inflammatory pathophysiology was modeled in vitro through 1) stimulation of primary human macrophages with anti–citrullinated protein antibody immune complexes (ICs), 2) RA fibroblast‐like synoviocyte (FLS) cultures stimulated with Toll‐like receptor (TLR) ligands, as well as 3) additional human primary cell cocultures exposed to inflammatory stimuli. Systemic lupus erythematosus (SLE) pathophysiology was simulated in human neutrophils, dendritic cells, B cells, and peripheral blood mononuclear cells stimulated with TLR ligands and SLE patient ICs. PF‐06650833 was evaluated in vivo in the rat collagen‐induced arthritis (CIA) model and the mouse pristane‐induced and MRL/lpr models of lupus. Finally, RNA sequencing data generated with whole blood samples from a phase I multiple‐ascending‐dose clinical trial of PF‐06650833 were used to test in vivo human pharmacology. Results: In vitro, PF‐06650833 inhibited human primary cell inflammatory responses to physiologically relevant stimuli generated with RA and SLE patient plasma. In vivo, PF‐06650833 reduced circulating autoantibody levels in the pristane‐induced and MRL/lpr murine models of lupus and protected against CIA in rats. In a phase I clinical trial (NCT02485769), PF‐06650833 demonstrated in vivo pharmacologic action pertinent to SLE by reducing whole blood interferon gene signature expression in healthy volunteers. Conclusion: These data demonstrate that inhibition of IRAK4 kinase activity can reduce levels of inflammation markers in humans and provide confidence in the rationale for clinical development of IRAK4 inhibitors for rheumatologic indications. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
5. Interaction between Human Papillomavirus-Encoded E6 Protein and AurB Induces Cell Immortalization and Proliferation—A Potential Target of Intervention.
- Author
-
Boon, Siaw Shi, Lee, Yin Ching, Yip, Ka Lai, Luk, Ho Yin, Xiao, Chuanyun, Yim, Man Kin, Chen, Zigui, and Chan, Paul Kay Sheung
- Subjects
IN vitro studies ,CELL migration ,IN vivo studies ,ANIMAL experimentation ,MICROBIOLOGICAL assay ,TELOMERASE ,CELL cycle proteins ,NEOPLASTIC cell transformation ,RISK assessment ,CELL division ,TRANSFERASES ,CELL proliferation ,PAPILLOMAVIRUS diseases ,CELL lines ,MICE ,DISEASE complications - Abstract
Simple Summary: This study identified that Aurora kinase B (AurB), a cellular protein that is upregulated in human cancers, is a bona fide interacting partner of HPVE6. HPVE6 complexes with AurB at the C-terminus end of E6, upstream of the E6-PBM. The AurB-E6 complex forms predominantly in the nucleus or mitotic cells. The positive correlation between E6 and AurB protein in HPV-positive cancer cells confers an increased cell proliferation and growth, and the eventual tumour formation. This study also underlined that the AurB-E6 complex could be a therapeutic target. However, the commercially available Aurora kinase inhibitors to date might not be selective toward HPV-positive cancer cells. Hence, this lack should be addressed. The human papillomavirus E6 and E7 oncoproteins interact with a different subset of host proteins, leading to dysregulation of the apoptotic, cell cycle, and signaling pathways. In this study, we identified, for the first time, that Aurora kinase B (AurB) is a bona fide interacting partner of E6. We systematically characterized the AurB-E6 complex formation and its consequences in carcinogenesis using a series of in vitro and cell-based assays. We also assessed the efficacy of Aurora kinase inhibitors in halting HPV-mediated carcinogenesis using in vitro and in vivo models. We showed that AurB activity was elevated in HPV-positive cells, and this correlated positively with the E6 protein level. E6 interacted directly with AurB in the nucleus or mitotic cells. A previously unidentified region of E6, located upstream of C-terminal E6-PBM, was important for AurB-E6 complex formation. AurB-E6 complex led to reduced AurB kinase activity. However, the AurB-E6 complex increased the hTERT protein level and its telomerase activity. On the other hand, AurB inhibition led to the inhibition of telomerase activity, cell proliferation, and tumor formation, even though this may occur in an HPV-independent manner. In summary, this study dissected the molecular mechanism of how E6 recruits AurB to induce cell immortalization and proliferation, leading to the eventual cancer development. Our findings revealed that the treatment of AZD1152 exerted a non-specific anti-tumor effect. Hence, a continuous effort to seek a specific and selective inhibitor that can halt HPV-mediated carcinogenesis should be warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Isoflurane Disrupts Postsynaptic Density-95 Protein Interactions Causing Neuronal Synapse Loss and Cognitive Impairment in Juvenile Mice via Canonical NO-mediated Protein Kinase-G Signaling.
- Author
-
Agarwal, Swati, Schaefer, Michele L., Krall, Caroline, and Johns, Roger A.
- Subjects
- *
ANIMAL experimentation , *CELL membranes , *NERVOUS system , *NUCLEOTIDES , *CELLULAR signal transduction , *TRANSFERASES , *RESEARCH funding , *ISOFLURANE , *PEPTIDES , *MICE - Abstract
Background: Inhalational anesthetics are known to disrupt PDZ2 domain-mediated protein-protein interactions of the postsynaptic density (PSD)-95 protein. The aim of this study is to investigate the underlying mechanisms in response to early isoflurane exposure on synaptic PSD-95 PDZ2 domain disruption that altered spine densities and cognitive function. The authors hypothesized that activation of protein kinase-G by the components of nitric oxide (NO) signaling pathway constitutes a mechanism that prevents loss of early dendritic spines and synapse in neurons and cognitive impairment in mice in response to disruption of PDZ2 domain of the PSD-95 protein.Methods: Postnatal day 7 mice were exposed to 1.5% isoflurane for 4 h or injected with 8 mg/kg active PSD-95 wild-type PDZ2 peptide or soluble guanylyl cyclase activator YC-1 along with their respective controls. Primary neurons at 7 days in vitro were exposed to isoflurane or PSD-95 wild-type PDZ2 peptide for 4 h. Coimmunoprecipitation, spine density, synapses, cyclic guanosine monophosphate-dependent protein kinase activity, and novel object recognition memory were assessed.Results: Exposure of isoflurane or PSD-95 wild-type PDZ2 peptide relative to controls causes the following. First, there is a decrease in PSD-95 coimmunoprecipitate relative to N-methyl-d-aspartate receptor subunits NR2A and NR2B precipitate (mean ± SD [in percentage of control]: isoflurane, 54.73 ± 16.52, P = 0.001; and PSD-95 wild-type PDZ2 peptide, 51.32 ± 12.93, P = 0.001). Second, there is a loss in spine density (mean ± SD [spine density per 10 µm]: control, 5.28 ± 0.56 vs. isoflurane, 2.23 ± 0.67, P < 0.0001; and PSD-95 mutant PDZ2 peptide, 4.74 ± 0.94 vs. PSD-95 wild-type PDZ2 peptide, 1.47 ± 0.87, P < 0.001) and a decrease in synaptic puncta (mean ± SD [in percentage of control]: isoflurane, 41.1 ± 14.38, P = 0.001; and PSD-95 wild-type PDZ2 peptide, 50.49 ± 14.31, P < 0.001). NO donor or cyclic guanosine monophosphate analog prevents the spines and synapse loss and decline in the cyclic guanosine monophosphate-dependent protein kinase activity, but this prevention was blocked by soluble guanylyl cyclase or protein kinase-G inhibitors in primary neurons. Third, there were deficits in object recognition at 5 weeks (mean ± SD [recognition index]: male, control, 64.08 ± 10.57 vs. isoflurane, 48.49 ± 13.41, P = 0.001, n = 60; and female, control, 67.13 ± 11.17 vs. isoflurane, 53.76 ± 6.64, P = 0.003, n = 58). Isoflurane-induced impairment in recognition memory was preventable by the introduction of YC-1.Conclusions: Activation of soluble guanylyl cyclase or protein kinase-G prevents isoflurane or PSD-95 wild-type PDZ2 peptide-induced loss of dendritic spines and synapse. Prevention of recognition memory with YC-1, a NO-independent activator of guanylyl cyclase, supports a role for the soluble guanylyl cyclase mediated protein kinase-G signaling in countering the effects of isoflurane-induced cognitive impairment.Editor’s Perspective: [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
7. Effect of Ephedra Herb on Erlotinib Resistance in c-Met-Overexpressing Non-Small-Cell Lung Cancer Cell Line, H1993, through Promotion of Endocytosis and Degradation of c-Met.
- Author
-
Hyuga, Sumiko, Hyuga, Masashi, Amakura, Yoshiaki, Yang, Jinwei, Mori, Eiko, Hakamatsuka, Takashi, Goda, Yukihiro, Odaguchi, Hiroshi, and Hanawa, Toshihiko
- Subjects
CELL proliferation ,ANIMAL experimentation ,CELL lines ,CELL receptors ,COMBINATION drug therapy ,DRUG resistance in cancer cells ,ENDOCYTOSIS ,EPHEDRA ,EPIDERMAL growth factor ,GENE expression ,LUNG cancer ,LYSOSOMES ,MEMBRANE proteins ,MICE ,PHOSPHORYLATION ,TANNINS ,TRANSFERASES ,XENOGRAFTS ,ERLOTINIB ,PHARMACODYNAMICS - Abstract
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKIs) are used to treat non-small-cell lung cancer (NSCLC), harboring an EGFR-activating mutation. However, acquired resistance to these treatments emerges after a few years. One of causes of resistance to EGFR-TKIs is a high level of c-Met amplification or c-Met protein overexpression/hyperactivation. Therefore, combination therapy with EGFR-TKIs and a c-Met inhibitor is thought to be effective treatment for patients with NSCLC resistance carrying c-Met amplification and/or protein hyperactivation. Ephedra Herb is a crude drug and is used in Japan as a component in many Kampo formulae. We previously reported that Ephedra Herb extract (EHE) inhibits HGF-induced phosphorylation of c-Met by preventing c-Met tyrosine kinase activity. Thus, we investigated the combination effect of EHE and erlotinib, an EGFR-TKI, on growth of H1993 cells, an erlotinib-resistant NSCLC cell line with overexpression of c-Met. The EHE and erlotinib combination proved to be effective in suppression of the growth of H1993 xenograft tumors and on inhibition of proliferation of H1993 cells, suggesting that EHE is effective in rescuing NSCLC cells from erlotinib resistance. Moreover, EHE not only inhibited the phosphorylation of c-Met, but also downregulated the expression of c-Met by facilitating clathrin-mediated endocytosis and lysosomal degradation of c-Met. EHE also promoted downregulation of the expression of EGFR and phosphorylation of EGFR. Ephedrine alkaloids-free Ephedra Herb extract (EFE) had the same effects as EHE, and the 40% MeOH fraction from EFE, which mainly contained the high-molecular mass condensed tannins, decreased the expression levels of c-Met, pMet, EGFR, and pEGFR to almost the same level as EFE. These results suggest that recovery from resistance to erlotinib by EHE is derived from the high-molecular mass condensed tannins and that EHE may be suitable for treatment of c-Met-overexpressing NSCLC with resistance to EGFR-TKIs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. PI3K activation within ventromedial prefrontal cortex regulates the expression of drug-seeking in two rodent species.
- Author
-
Szumlinski, Karen K., Ary, Alexis W., Shin, Christina B., Wroten, Melissa G., Courson, Justin, Miller, Bailey W., Ruppert‐Majer, Micaela, Hiller, John W., Shahin, John R., Ben‐Shahar, Osnat, Kippin, Tod E., Ruppert-Majer, Micaela, and Ben-Shahar, Osnat
- Subjects
PREFRONTAL cortex ,PROTEIN kinase B ,COCAINE abuse ,RODENTS ,DRUG-seeking behavior ,FRONTAL lobe ,BIOLOGICAL models ,ANIMAL behavior ,SUBSTANCE abuse ,PHOSPHOTRANSFERASES ,DESIRE ,LEARNING ,RATS ,SELF medication ,TRANSFERASES ,COCAINE ,RESEARCH funding ,DOPAMINE uptake inhibitors ,COMPULSIVE behavior ,PHOSPHORYLATION ,MICE ,ANIMALS ,PROMPTS (Psychology) ,PHARMACODYNAMICS - Abstract
Phosphatidylinositide 3-kinases (PI3Ks) are intracellular signal transducer enzymes that recruit protein kinase B (aka Akt) to the cell membrane, the subsequent activation of which regulates many cellular functions. PI3K/Akt activity is up-regulated within mesocorticolimbic structures in animal models of alcoholism, but less is known regarding PI3K/Akt activity in animal models of cocaine addiction. Given that prefrontal cortex (PFC) is grossly dysregulated in addiction, we studied how cocaine affects protein indices of PFC PI3K/Akt activity in rat and mouse models and examined the relevance of PI3K activity for cocaine-related learning. Immunoblotting of mouse medial PFC at 3 weeks withdrawal from a cocaine-sensitization regimen (seven injections of 30 mg/kg, intraperitoneal [IP]) revealed increased kinase activity, as did immunoblotting of tissue from the ventral PFC of rats with a history of long-access intravenous cocaine self-administration (0.25 mg/0.1 mL infusion; 10 days of 6 h/d cocaine access). Interestingly, increased Akt phosphorylation was observed in rat ventromedial PFC at both 3- and 30-day withdrawal only in animals re-exposed to cocaine-associated cues. A conditioned place-preference paradigm in mice and a cue-elicited drug-seeking test in rats were conducted to determine the functional relevance for elevated PI3K activity for addiction-related behavior. In both cases, an intra-PFC infusion of the PI3K inhibitor wortmannin (50μM) reduced drug-seeking behavior. Taken together, this cross-species, interdisciplinary, study provides convincing evidence that cocaine history produces an enduring increase in PI3K/Akt-dependent signaling within the more ventral aspect of the PFC that is relevant to behavioral reactivity to drug-associated cues/contexts. As such, PI3K inhibitors may well serve as an effective strategy for reducing drug cue reactivity and craving in cocaine addiction. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Leucine-rich repeat kinase 2 positively regulates inflammation and down-regulates NF-κB p50 signaling in cultured microglia cells.
- Author
-
Russo, Isabella, Berti, Giulia, Plotegher, Nicoletta, Bernardo, Greta, Filograna, Roberta, Bubacco, Luigi, and Greggio, Elisa
- Subjects
INFLAMMATION ,DARDARIN ,MICROGLIA ,PHOSPHORYLATION ,NF-kappa B ,INFLAMMATION prevention ,CELL metabolism ,BIOCHEMISTRY ,PROTEINS ,CELL culture ,ANIMAL experimentation ,CELLULAR signal transduction ,PHENOMENOLOGY ,TRANSFERASES ,RESEARCH funding ,INFLAMMATORY mediators ,MICE ,PHYSIOLOGY ,CHEMICAL inhibitors - Abstract
Background: Over-activated microglia and chronic neuroinflammation contribute to dopaminergic neuron degeneration and progression of Parkinson's disease (PD). Leucine-rich repeat kinase 2 (LRRK2), a kinase mutated in autosomal dominantly inherited and sporadic PD cases, is highly expressed in immune cells, in which it regulates inflammation through a yet unclear mechanism.Methods: Here, using pharmacological inhibition and cultured Lrrk2 (-/-) primary microglia cells, we validated LRRK2 as a positive modulator of inflammation and we investigated its specific function in microglia cells.Results: Inhibition or genetic deletion of LRRK2 causes reduction of interleukin-1β and cyclooxygenase-2 expression upon lipopolysaccharide-mediated inflammation. LRRK2 also takes part of the signaling trigged by α-synuclein fibrils, which culminates in induction of inflammatory mediators. At the molecular level, loss of LRRK2 or inhibition of its kinase activity results in increased phosphorylation of nuclear factor kappa-B (NF-κB) inhibitory subunit p50 at S337, a protein kinase A (PKA)-specific phosphorylation site, with consequent accumulation of p50 in the nucleus.Conclusions: Taken together, these findings point to a role of LRRK2 in microglia activation and sustainment of neuroinflammation and in controlling of NF-κB p50 inhibitory signaling. Understanding the molecular pathways coordinated by LRRK2 in activated microglia cells after pathological stimuli such us fibrillar α-synuclein holds the potential to provide novel targets for PD therapeutics. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
10. Role of Src kinase in regulating protein kinase C mediated phosphorylation of TRPV1.
- Author
-
Robilotto, Gabriella L., Mohapatra, Durga P., Shepherd, Andrew J., and Mickle, Aaron D.
- Subjects
CALCIUM metabolism ,CHRONIC pain ,ANIMAL experimentation ,SENSORY ganglia ,TRANSFERASES ,RESEARCH funding ,CALCIUM ,SOLUTION (Chemistry) ,CARRIER proteins ,MICE ,HYPERALGESIA ,ANIMALS ,PHOSPHORYLATION ,CAPSAICIN - Abstract
Background: Transient receptor potential vanilloid-1 (TRPV1), activated by heat, acidic pH, endogenous vanilloids and capsaicin, is essential for thermal hyperalgesia. Under inflammatory conditions, phosphorylation of TRPV1 by protein kinase C (PKC) can sensitize the channel and decrease the activation threshold. Src kinase also phosphorylates TRPV1, promoting channel trafficking to the plasma membrane. These post-translational modifications are important for several chronic pain conditions. This study presents a previously undescribed relationship between Src and PKC phosphorylation of TRPV1, influencing the thermal hypersensitivity associated with TRPV1 activation.Methods: We assessed TRPV1 channel activity using intracellular calcium imaging and patch-clamp electrophysiology in mouse dorsal root ganglion cultures. Additionally, we used behavioural experiments to evaluate plantar thermal sensitivity following intraplantar injections of activators of known modulators of TRPV1 with and without an Src antagonist.Results: Using calcium imaging and patch-clamp techniques, we demonstrated that pharmacological inhibition of Src kinase or mutation of the Src phosphorylation site on TRPV1 prevented PKC but not PKA-mediated sensitization of TRPV1 in vitro. We found that intraplantar injection of the PKC activator phorbol 12-myristate 13-acetate (PMA) or bradykinin produces thermal hypersensitivity that can be attenuated by pharmacological inhibition of Src. Additionally, complete Freund's Adjuvant (CFA)-induced inflammatory hypersensitivity could also be attenuated by local Src kinase inhibition.Conclusions: Our data demonstrate that Src phosphorylation is critical for PKC-mediated sensitization of TRPV1. Further, in a model of inflammatory pain, CFA, Src kinase inhibition could reduce thermal hypersensitivity. Targeting of Src kinase may have analgesic benefits in inflammatory pain conditions.Significance: Src kinase-mediated phosphorylation of TRPV1 is a critical regulator of the PKC-induced sensitization induced by multiple inflammatory mediators. This suggest a new regulatory mechanism governing TRPV1 function and a potential therapeutic target for inflammatory type pain, including cancer pain where Src antagonists are currently utilized. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
11. Pharmacological Inhibition of the Skeletal IKKβ Reduces Breast Cancer-Induced Osteolysis.
- Author
-
Marino, Silvia, Bishop, Ryan T., Mollat, Patrick, and Idris, Aymen I.
- Subjects
BREAST cancer treatment ,PHARMACOLOGY ,BONE metastasis ,BONE remodeling ,OSTEOBLASTS ,OSTEOBLAST metabolism ,ANIMAL experimentation ,APOPTOSIS ,BONE resorption ,BONE growth ,BONE tumors ,BREAST tumors ,CELL differentiation ,CELL lines ,CELLULAR signal transduction ,COMPUTED tomography ,CULTURE media (Biology) ,MACROPHAGES ,METASTASIS ,MICE ,PROTEOLYTIC enzymes ,RESEARCH funding ,TRANSFERASES - Abstract
IKKβ has previously been implicated in breast cancer bone metastasis and bone remodelling. However, the contribution of IKKβ expressed by bone cells of the tumour microenvironment to breast cancer-induced osteolysis has yet to be investigated. Here, we studied the effects of the verified selective IKKβ inhibitors IKKβIII or IKKβV on osteoclast formation and osteoblast differentiation in vitro and in vivo, human and mouse breast cancer cells' support for osteoclast formation and signalling in vitro and osteolysis ex vivo and in immunocompetent mice after supracalvarial injection of human MDA-MB-231 conditioned medium or intra-cardiac injection of syngeneic 4T1 breast cancer cells. Pre-treatment with IKKβIII or IKKβV prior to exposure to tumour-derived factors from human and mouse breast cancer cell lines protected against breast cancer-induced osteolysis in two independent immunocompetent mouse models of osteolysis and the ex vivo calvarial bone organ system. Detailed functional and mechanistic studies showed that direct inhibition of IKKβ kinase activity in osteoblasts and osteoclasts was associated with significant reduction of osteoclast formation, enhanced osteoclast apoptosis and reduced the ability of osteoblasts to support osteoclastogenesis in vitro. When combined with previous findings that suggest NFκB inhibition reduces breast cancer tumorigenesis and metastasis our present findings have an important clinical implication on raising the possibility that IKKβ inhibitors, as bone anabolics, osteoclast inhibitors as well as anti-metastatic agents, may have advantages over anti-osteoclasts agents in the treatment of both skeletal and non-skeletal complications associated with metastatic breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
12. Eukaryotic-like Kinase Expression in Enterohemorrhagic Escherichia coli: Potential for Enhancing Host Aggressive Inflammatory Response.
- Author
-
Tao Li, Zhan Li, Fanghong Chen, Xiong Liu, Nianzhi Ning, Jie Huang, Hui Wang, Li, Tao, Li, Zhan, Chen, Fanghong, Liu, Xiong, Ning, Nianzhi, Huang, Jie, and Wang, Hui
- Subjects
KINASES ,ESCHERICHIA coli O157:H7 ,IMMUNE response ,VIRULENCE of Escherichia coli ,KERATINOCYTES ,INVERTEBRATE metabolism ,METABOLISM ,ANIMAL experimentation ,ESCHERICHIA coli ,ESCHERICHIA coli diseases ,INFLAMMATION ,INVERTEBRATES ,MICE ,TRANSFERASES - Abstract
Enterohemorrhagic Escherichia coli (EHEC) or other attaching/effacing pathogen infections often cause host intestinal inflammation and pathology, which is thought to result in part from a host aggressive innate immune response. However, few effectors that play an important role in this pathology change have been reported. In this study, we discovered a previously unknown EHEC effector, Stk (putative serine/threonine kinase), which induces host aggressive inflammatory response during EHEC infection. Interestingly, homologous proteins of Stk are widely distributed in many pathogens. After translocating into the infected host cells, Stk efficiently phosphorylates IκBα and activates the NF-κB pathway. In EHEC-infected mice, Stk increases serum keratinocyte-derived cytokine (KC) levels and hyperactivates the inflammatory response of the colon, intensifying pathological injury of the colon. The virulence of Stk is based on its eukaryotic-like kinase activity. In conclusion, our data suggest that Stk is a new effector that induces the host aggressive inflammatory response during EHEC infection. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
13. Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma.
- Author
-
Stauffer, Stacey, Roth, Jacob S., Hernandez, Edjay R., Kowalczyk, Joshua T., Sealover, Nancy E., Hebron, Katie E., James, Amy, Isanogle, Kristine A., Riffle, Lisa A., Ileva, Lilia, Luo, Xiaoling, Chen, Jin-Qiu, Kedei, Noemi, Kortum, Robert L., Lei, Haiyan, Shern, Jack F., Kalen, Joseph D., Edmondson, Elijah F., Hall, Matthew D., and Difilippantonio, Simone
- Subjects
IN vitro studies ,CANCER relapse ,RESEARCH funding ,ANTINEOPLASTIC agents ,CELL proliferation ,APOPTOSIS ,XENOGRAFTS ,MONOCLONAL antibodies ,CELL lines ,MICE ,DRUG efficacy ,ANIMAL experimentation ,MTOR inhibitors ,TRANSFERASES ,NEUROBLASTOMA ,CELL receptors ,PHARMACODYNAMICS - Abstract
Simple Summary: The prognosis for patients with relapsed neuroblastoma is poor, and novel treatment options for these patients are needed. Some relapsed neuroblastoma tumors harbor activating mutations in the RAS/MAPK pathway. In prior studies, single agent MEK or IGF1R inhibitors induced transient responses as single agents in neuroblastoma models. In this study, we tested the efficacy of a combination of the MEK inhibitor trametinib and the IGF1R inhibitor ganitumab in RAS-mutated neuroblastoma models. While the trametinib/ganitumab combination decreased cell viability and tumor growth, the combination did not prevent metastasis of RAS-mutated neuroblastoma. Therefore, further studies on the effect of trametinib and ganitumab on neuroblastoma metastasis are necessary before initiating clinical trials of this combination of targeted agents in patients with relapsed neuroblastoma. Activating mutations in the RAS/MAPK pathway are observed in relapsed neuroblastoma. Preclinical studies indicate that these tumors have an increased sensitivity to inhibitors of the RAS/MAPK pathway, such as MEK inhibitors. MEK inhibitors do not induce durable responses as single agents, indicating a need to identify synergistic combinations of targeted agents to provide therapeutic benefit. We previously showed preclinical therapeutic synergy between a MEK inhibitor, trametinib, and a monoclonal antibody specific for IGF1R, ganitumab in RAS-mutated rhabdomyosarcoma. Neuroblastoma cells, like rhabdomyosarcoma cells, are sensitive to the inhibition of the RAS/MAPK and IGF1R/AKT/mTOR pathways. We hypothesized that the combination of trametinib and ganitumab would be effective in RAS-mutated neuroblastoma. In this study, trametinib and ganitumab synergistically suppressed neuroblastoma cell proliferation and induced apoptosis in cell culture. We also observed a delay in tumor initiation and prolongation of survival in heterotopic and orthotopic xenograft models treated with trametinib and ganitumab. However, the growth of both primary and metastatic tumors was observed in animals receiving the combination of trametinib and ganitumab. Therefore, more preclinical work is necessary before testing this combination in patients with relapsed or refractory RAS-mutated neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Src kinase-targeted anti-inflammatory activity of davallialactone from Inonotus xeranticus in lipopolysaccharide-activated RAW264.7 cells.
- Author
-
Lee, Y. G., Lee, W. M., Kim, J. Y., Lee, J. Y., Lee, I.-K., Yun, B.-S., Rhee, M. H., and Cho, J. Y.
- Subjects
MUSHROOMS ,MACROPHAGES ,CELL lines ,PROSTAGLANDINS ,CYTOKINES ,PHOSPHORYLATION ,PHARMACOLOGY ,BIOLOGICAL models ,DRUG delivery systems ,LIPOPOLYSACCHARIDES ,BIOCHEMISTRY ,RESEARCH ,ANTI-inflammatory agents ,INFLAMMATION ,ANIMAL experimentation ,RESEARCH methodology ,ORGANIC compounds ,CELL receptors ,MEDICAL cooperation ,EVALUATION research ,CELLULAR signal transduction ,PHENOMENOLOGY ,COMPARATIVE studies ,TRANSFERASES ,MICE ,PHARMACODYNAMICS - Abstract
Background and purpose:Mushrooms are popular both as food and as a source of natural compounds of biopharmaceutical interest. Some mushroom-derived compounds such as β-glucan have been shown to be immunostimulatory; this study explores the anti-inflammatory properties of hispidin analogues derived from the mushroom, Inonotus xeranticus. We sought to identify the molecular mechanism of action of these hispidin analogues by determining their effects on lipopolysaccharide (LPS)-mediated inflammatory responses in a macrophage cell line.Experimental approach:The production of inflammatory mediators was determined by Griess assay, reverse transcription-PCR and ELISA. The inhibitory effect of davalliactone on LPS-induced activation of signalling cascades was assessed by western blotting, immunoprecipitation and direct kinase assay.Key results:In activated RAW264.7 cells, davallialactone strongly downregulated LPS-mediated inflammatory responses, including NO production, prostaglandin E
2 release, expression of proinflammatory cytokine genes and cell surface expression of co-stimulatory molecules. Davallialactone treatment did not alter cell viability or morphology. Davallialactone was found to exert its anti-inflammatory effects by inhibiting a signalling cascade that activates nuclear factor kappa B via PI3K, Akt and IKK, but not mitogen-activated protein kinases. Treatment with davallialactone affected the phosphorylation of these signalling proteins, but not their level of expression. These inhibitory effects were not due to the interruption of toll-like receptor 4 binding to CD14. In particular, davallialactone strongly inhibited the LPS-induced phosphorylation and kinase activity of Src, implying that Src may be a potential pharmacological target of davallialactone.Conclusions and implications:Our data suggest that davallialactone, a small molecule found in edible mushrooms, has anti-inflammatory activity. Davallialactone can be developed as a pharmaceutically valuable anti-Src kinase agent.British Journal of Pharmacology (2008) 154, 852–863; doi:10.1038/bjp.2008.136; published online 5 May 2008 [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
15. Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy.
- Author
-
Faisal, Amir, Mak, Grace W Y, Gurden, Mark D, Xavier, Cristina P R, Anderhub, Simon J, Innocenti, Paolo, Westwood, Isaac M, Naud, Sébastien, Hayes, Angela, Box, Gary, Valenti, Melanie R, De Haven Brandon, Alexis K, O'Fee, Lisa, Schmitt, Jessica, Woodward, Hannah L, Burke, Rosemary, vanMontfort, Rob L M, Blagg, Julian, Raynaud, Florence I, and Eccles, Suzanne A
- Subjects
- *
ANIMAL experimentation , *CELL lines , *CELLS , *MICE , *PROTEIN-tyrosine kinases , *TRANSFERASES , *TUMORS , *PROTEIN kinase inhibitors , *CELL cycle proteins , *CHEMICAL inhibitors - Abstract
Background: The main role of the cell cycle is to enable error-free DNA replication, chromosome segregation and cytokinesis. One of the best characterised checkpoint pathways is the spindle assembly checkpoint, which prevents anaphase onset until the appropriate attachment and tension across kinetochores is achieved. MPS1 kinase activity is essential for the activation of the spindle assembly checkpoint and has been shown to be deregulated in human tumours with chromosomal instability and aneuploidy. Therefore, MPS1 inhibition represents an attractive strategy to target cancers.Methods: To evaluate CCT271850 cellular potency, two specific antibodies that recognise the activation sites of MPS1 were used and its antiproliferative activity was determined in 91 human cancer cell lines. DLD1 cells with induced GFP-MPS1 and HCT116 cells were used in in vivo studies to directly measure MPS1 inhibition and efficacy of CCT271850 treatment.Results: CCT271850 selectively and potently inhibits MPS1 kinase activity in biochemical and cellular assays and in in vivo models. Mechanistically, tumour cells treated with CCT271850 acquire aberrant numbers of chromosomes and the majority of cells divide their chromosomes without proper alignment because of abrogation of the mitotic checkpoint, leading to cell death. We demonstrated a moderate level of efficacy of CCT271850 as a single agent in a human colorectal carcinoma xenograft model.Conclusions: CCT271850 is a potent, selective and orally bioavailable MPS1 kinase inhibitor. On the basis of in vivo pharmacodynamic vs efficacy relationships, we predict that more than 80% inhibition of MPS1 activity for at least 24 h is required to achieve tumour stasis or regression by CCT271850. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
16. The Roles of Unfolded Protein Response Pathways in Chlamydia Pathogenesis.
- Author
-
George, Zenas, Omosun, Yusuf, Azenabor, Anthony A., Partin, James, Joseph, Kahaliah, Ellerson, Debra, Qing He, Eko, Francis, Bandea, Claudiu, Svoboda, Pavel, Pohl, Jan, Black, Carolyn M., Igietseme, Joseph U., and He, Qing
- Subjects
ANIMALS ,APOPTOSIS ,BIOCHEMISTRY ,CELL physiology ,CELLULAR signal transduction ,CHLAMYDIA ,CHLAMYDIA infections ,ESTERASES ,PHENOMENOLOGY ,MICE ,PEPTIDES ,PROTEINS ,TRANSFERASES - Abstract
Chlamydia is an obligate intracellular bacterium that relies on host cells for essential nutrients and adenosine triphosphate (ATP) for a productive infection. Although the unfolded protein response (UPR) plays a major role in certain microbial infectivity, its role in chlamydial pathogenesis is unknown. We hypothesized that Chlamydia induces UPR and exploits it to upregulate host cell uptake and metabolism of glucose, production of ATP, phospholipids, and other molecules required for its replicative development and host survival. Using a combination of biochemical and pathway inhibition assays, we showed that the 3 UPR pathway transducers-protein kinase RNA-activated (PKR)-like ER kinase (PERK), inositol-requiring enzyme-1α (IRE1α), and activating transcription factor-6α (ATF6α)-were activated during Chlamydia infection. The kinase activity of PERK and ribonuclease (RNase) of IRE1α mediated the upregulation of hexokinase II and production of ATP via substrate-level phosphorylation. In addition, the activation of PERK and IRE1α promoted autophagy formation and apoptosis resistance for host survival. Moreover, the activation of IRE1α resulted in the generation of spliced X-box binding protein 1 (sXBP1) and upregulation of lipid production. The vital role of UPR pathways in Chlamydia development and pathogenesis could lead to the identification of potential molecular targets for therapeutics against Chlamydia. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
17. Insulin receptor Thr1160 phosphorylation mediates lipid-induced hepatic insulin resistance.
- Author
-
Petersen, Max C., Madiraju, Anila K., Gassaway, Brandon M., Marcel, Michael, Nasiri, Ali R., Butrico, Gina, Marcucci, Melissa J., Dongyan Zhang, Abulizi, Abudukadier, Xian-Man Zhang, Philbrick, William, Hubbard, Stevan R., Jurczak, Michael J., Samuel, Varman T., Rinehart, Jesse, Shulman, Gerald I., Zhang, Dongyan, and Zhang, Xian-Man
- Subjects
- *
FATTY liver , *TYPE 2 diabetes , *INSULIN resistance , *INSULIN receptors , *PHOSPHORYLATION , *DISEASE risk factors , *AMINO acids , *ANIMAL experimentation , *CELL receptors , *CELLULAR signal transduction , *FAT content of food , *GLYCOGEN , *LIVER , *MICE , *GENETIC mutation , *RESEARCH funding , *TRANSFERASES - Abstract
Nonalcoholic fatty liver disease (NAFLD) is a risk factor for type 2 diabetes (T2D), but whether NAFLD plays a causal role in the pathogenesis of T2D is uncertain. One proposed mechanism linking NAFLD to hepatic insulin resistance involves diacylglycerol-mediated (DAG-mediated) activation of protein kinase C-ε (PKCε) and the consequent inhibition of insulin receptor (INSR) kinase activity. However, the molecular mechanism underlying PKCε inhibition of INSR kinase activity is unknown. Here, we used mass spectrometry to identify the phosphorylation site Thr1160 as a PKCε substrate in the functionally critical INSR kinase activation loop. We hypothesized that Thr1160 phosphorylation impairs INSR kinase activity by destabilizing the active configuration of the INSR kinase, and our results confirmed this prediction by demonstrating severely impaired INSR kinase activity in phosphomimetic T1160E mutants. Conversely, the INSR T1160A mutant was not inhibited by PKCε in vitro. Furthermore, mice with a threonine-to-alanine mutation at the homologous residue Thr1150 (InsrT1150A mice) were protected from high fat diet-induced hepatic insulin resistance. InsrT1150A mice also displayed increased insulin signaling, suppression of hepatic glucose production, and increased hepatic glycogen synthesis compared with WT controls during hyperinsulinemic clamp studies. These data reveal a critical pathophysiological role for INSR Thr1160 phosphorylation and provide further mechanistic links between PKCε and INSR in mediating NAFLD-induced hepatic insulin resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model.
- Author
-
Matte, Alessandro, Federti, Enrica, Kung, Charles, Kosinski, Penelope A., Narayanaswamy, Rohini, Russo, Roberta, Federico, Giorgia, Carlomagno, Francesca, Desbats, Maria Andrea, Salviati, Leonardo, Leboeuf, Christophe, Valenti, Maria Teresa, Turrini, Francesco, Janin, Anne, Shaoxia Yu, Beneduce, Elisabetta, Ronseaux, Sebastien, Iatcenko, Iana, Dang, Lenny, and Ganz, Tomas
- Subjects
- *
PYRUVATE kinase , *LABORATORY mice , *PYRUVATES , *FETAL hemoglobin , *CELL survival , *ANIMAL disease models , *ANEMIA , *QUINOLINE , *BIOLOGICAL models , *RESEARCH , *HETEROCYCLIC compounds , *HEMOLYSIS & hemolysins , *ANIMAL experimentation , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *ENZYMES , *TRANSFERASES , *BETA-Thalassemia , *MICE - Abstract
Anemia in β-thalassemia is related to ineffective erythropoiesis and reduced red cell survival. Excess free heme and accumulation of unpaired α-globin chains impose substantial oxidative stress on β-thalassemic erythroblasts and erythrocytes, impacting cell metabolism. We hypothesized that increased pyruvate kinase activity induced by mitapivat (AG-348) in the Hbbth3/+ mouse model for β-thalassemia would reduce chronic hemolysis and ineffective erythropoiesis through stimulation of red cell glycolytic metabolism. Oral mitapivat administration ameliorated ineffective erythropoiesis and anemia in Hbbth3/+ mice. Increased ATP, reduced reactive oxygen species production, and reduced markers of mitochondrial dysfunction associated with improved mitochondrial clearance suggested enhanced metabolism following mitapivat administration in β-thalassemia. The amelioration of responsiveness to erythropoietin resulted in reduced soluble erythroferrone, increased liver Hamp expression, and diminished liver iron overload. Mitapivat reduced duodenal Dmt1 expression potentially by activating the pyruvate kinase M2-HIF2α axis, representing a mechanism additional to Hamp in controlling iron absorption and preventing β-thalassemia-related liver iron overload. In ex vivo studies on erythroid precursors from patients with β-thalassemia, mitapivat enhanced erythropoiesis, promoted erythroid maturation, and decreased apoptosis. Overall, pyruvate kinase activation as a treatment modality for β-thalassemia in preclinical model systems had multiple beneficial effects in the erythropoietic compartment and beyond, providing a strong scientific basis for further clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
19. RACK1 Promotes Meningioma Progression by Activation of NF-κB Pathway via Preventing CSNK2B from Ubiquitination Degradation.
- Author
-
Maalim, Ali Abdi, Wang, Zihan, Huang, Yimin, and Lei, Ting
- Subjects
BIOCHEMISTRY ,DISEASE progression ,STATISTICS ,IN vivo studies ,SEQUENCE analysis ,STAINS & staining (Microscopy) ,PHENOMENOLOGICAL biology ,ANIMAL experimentation ,COLONY-forming units assay ,WESTERN immunoblotting ,ONE-way analysis of variance ,CELL receptors ,NF-kappa B ,PRECIPITIN tests ,CELLULAR signal transduction ,CELL cycle ,MENINGIOMA ,TRANSFERASES ,MASS spectrometry ,GENE expression profiling ,CELL proliferation ,ENZYME-linked immunosorbent assay ,DESCRIPTIVE statistics ,RESEARCH funding ,CELL lines ,STATISTICAL correlation ,DATA analysis ,DATA analysis software ,MICE - Abstract
Simple Summary: Malignant meningiomas have high aggressiveness and recurrence rates and a poor prognosis, with no clear pharmacological treatment available. The study aims to investigate the progression mechanism of malignant meningiomas and the targets of intervention. RACK1 and CSNK2B have been shown to promote tumor progression but their roles in meningiomas are not clear. In this study, we will investigate the roles of RACK1-CSNK2B in meningiomas and search for targets to inhibit the progression of meningiomas. Higher-grade meningiomas (WHO grade II and III) are characterized by aggressive invasiveness and high postoperative recurrence rates. The prognosis remains inadequate even with adjuvant radiotherapy and currently there is no definitive pharmacological treatment strategy and target for malignant meningiomas. This study aims to unveil the mechanisms driving the malignant progression of meningiomas and to identify potential inhibitory targets, with significant clinical implications. Implementing techniques such as protein immunoprecipitation, mass spectrometry, RNA interference, and transcriptome sequencing, we investigated the malignancy mechanisms in meningioma cell lines IOMM-LEE and CH157-MN. Additionally, in vivo experiments were carried out on nude mice. We discovered a positive correlation between meningioma malignancy and the levels of the receptor for activated C kinase 1 (RACK1), which interacts with CSNK2B, the β subunit of casein kinase 2 (CK2), inhibiting its ubiquitination and subsequent degradation. This inhibition allows CK2 to activate the NF-κb pathway, which increases the transcription of CDK4 and cyclin D3, resulting in the transition of the cell cycle into the G2/M phase. The RACK1 inhibitor, harringtonolide (HA), significantly suppressed the malignant tendencies of meningioma cells. Our study suggests that RACK1 may play a role in the malignant progression of meningiomas, and therefore, targeting RACK1 could emerge as an effective strategy for reducing the malignancy of these tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Cardiac Stim1 Silencing Impairs Adaptive Hypertrophy and Promotes Heart Failure Through Inactivation of mTORC2/Akt Signaling.
- Author
-
Bénard, Ludovic, Jae Gyun Oh, Cacheux, Marine, Ahyoung Lee, Nonnenmacher, Mathieu, Matasic, Daniel S., Kohlbrenner, Erik, Changwon Kho, Pavoine, Catherine, Hajjar, Roger J., Hulot, Jean-Sébastien, Oh, Jae Gyun, Lee, Ahyoung, and Kho, Changwon
- Subjects
- *
HEART cells , *HEART failure , *HEART diseases , *THERAPEUTICS , *CARDIAC hypertrophy , *IN vivo studies , *GENE therapy , *CELL metabolism , *PROTEIN metabolism , *AMINO acids , *ANIMAL experimentation , *BIOLOGICAL models , *CALCIUM , *CARRIER proteins , *CELLULAR signal transduction , *GENES , *MOLECULAR probes , *MICE , *PHOSPHORYLATION , *PROTEINS , *RESEARCH funding , *RNA , *TRANSFERASES , *VENTRICULAR remodeling , *CHEMICAL inhibitors - Abstract
Background: Stromal interaction molecule 1 (STIM1) is a dynamic calcium signal transducer implicated in hypertrophic growth of cardiomyocytes. STIM1 is thought to act as an initiator of cardiac hypertrophic response at the level of the sarcolemma, but the pathways underpinning this effect have not been examined.Methods and Results: To determine the mechanistic role of STIM1 in cardiac hypertrophy and during the transition to heart failure, we manipulated STIM1 expression in mice cardiomyocytes by using in vivo gene delivery of specific short hairpin RNAs. In 3 different models, we found that Stim1 silencing prevents the development of pressure overload-induced hypertrophy but also reverses preestablished cardiac hypertrophy. Reduction in STIM1 expression promoted a rapid transition to heart failure. We further showed that Stim1 silencing resulted in enhanced activity of the antihypertrophic and proapoptotic GSK-3β molecule. Pharmacological inhibition of glycogen synthase kinase-3 was sufficient to reverse the cardiac phenotype observed after Stim1 silencing. At the level of ventricular myocytes, Stim1 silencing or inhibition abrogated the capacity for phosphorylation of Akt(S473), a hydrophobic motif of Akt that is directly phosphorylated by mTOR complex 2. We found that Stim1 silencing directly impaired mTOR complex 2 kinase activity, which was supported by a direct interaction between STIM1 and Rictor, a specific component of mTOR complex 2.Conclusions: These data support a model whereby STIM1 is critical to deactivate a key negative regulator of cardiac hypertrophy. In cardiomyocytes, STIM1 acts by tuning Akt kinase activity through activation of mTOR complex 2, which further results in repression of GSK-3β activity. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
21. Salt-inducible kinase 1 maintains HDAC7 stability to promote pathologic cardiac remodeling.
- Author
-
Hsu, Austin, Qiming Duan, McMahon, Sarah, Yu Huang, Wood, Sarah A. B., Gray, Nathanael S., Biao Wang, Bruneau, Benoit G., Haldar, Saptarsi M., Duan, Qiming, Huang, Yu, Wood, Sarah Ab, and Wang, Biao
- Subjects
- *
INDUCED pluripotent stem cells , *HEART failure , *CELL growth , *DOBUTAMINE , *CELL metabolism , *RESEARCH , *VENTRICULAR remodeling , *ANIMAL experimentation , *RESEARCH methodology , *EVALUATION research , *MEDICAL cooperation , *HYDROLASES , *RATS , *COMPARATIVE studies , *TRANSFERASES , *CELLS , *RESEARCH funding , *MICE , *PHOSPHORYLATION - Abstract
Salt-inducible kinases (SIKs) are key regulators of cellular metabolism and growth, but their role in cardiomyocyte plasticity and heart failure pathogenesis remains unknown. Here, we showed that loss of SIK1 kinase activity protected against adverse cardiac remodeling and heart failure pathogenesis in rodent models and cardiomyocytes derived from human induced pluripotent stem cells. We found that SIK1 phosphorylated and stabilized histone deacetylase 7 (HDAC7) protein during cardiac stress, an event that is required for pathologic cardiomyocyte remodeling. Gain- and loss-of-function studies of HDAC7 in cultured cardiomyocytes implicated HDAC7 as a prohypertrophic signaling effector that can induce c-Myc expression, indicating a functional departure from the canonical MEF2 corepressor function of class IIa HDACs. Taken together, our findings reveal what we believe to be a previously unrecognized role for a SIK1/HDAC7 axis in regulating cardiac stress responses and implicate this pathway as a potential target in human heart failure. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. microRNA-21-5p dysregulation in exosomes derived from heart failure patients impairs regenerative potential.
- Author
-
Li Qiao, Shiqi Hu, Suyun Liu, Hui Zhang, Hong Ma, Ke Huang, Zhenhua Li, Teng Su, Vandergriff, Adam, Junnan Tang, Allen, Tyler, Phuong-Uyen Dinh, Cores, Jhon, Qi Yin, Yongjun Li, Ke Cheng, Qiao, Li, Hu, Shiqi, Liu, Suyun, and Zhang, Hui
- Subjects
- *
HEART failure patients , *PTEN protein , *EXOSOMES , *HEART cells , *VENTRICULAR remodeling , *RNA metabolism , *CELL metabolism , *HEART physiology , *HEART metabolism , *RESEARCH , *MYOCARDIUM , *REGENERATION (Biology) , *NEOVASCULARIZATION , *ANIMAL experimentation , *RESEARCH methodology , *RNA , *EVALUATION research , *MEDICAL cooperation , *CELLULAR signal transduction , *COMPARATIVE studies , *TRANSFERASES , *CELLS , *RESEARCH funding , *CONNECTIVE tissue cells , *EPITHELIAL cells , *HEART failure , *MICE - Abstract
Exosomes, as functional paracrine units of therapeutic cells, can partially reproduce the reparative properties of their parental cells. The constitution of exosomes, as well as their biological activity, largely depends on the cells that secrete them. We isolated exosomes from explant-derived cardiac stromal cells from patients with heart failure (FEXO) or from normal donor hearts (NEXO) and compared their regenerative activities in vitro and in vivo. Patients in the FEXO group exhibited an impaired ability to promote endothelial tube formation and cardiomyocyte proliferation in vitro. Intramyocardial injection of NEXO resulted in structural and functional improvements in a murine model of acute myocardial infarction. In contrast, FEXO therapy exacerbated cardiac function and left ventricular remodeling. microRNA array and PCR analysis revealed dysregulation of miR-21-5p in FEXO. Restoring miR-21-5p expression rescued FEXO's reparative function, whereas blunting miR-21-5p expression in NEXO diminished its therapeutic benefits. Further mechanistic studies revealed that miR-21-5p augmented Akt kinase activity through the inhibition of phosphatase and tensin homolog. Taken together, the heart failure pathological condition altered the miR cargos of cardiac-derived exosomes and impaired their regenerative activities. miR-21-5p contributes to exosome-mediated heart repair by enhancing angiogenesis and cardiomyocyte survival through the phosphatase and tensin homolog/Akt pathway. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
23. Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines.
- Author
-
Peasland, A., Wang, L.-Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W. A., Sarkaria, J., Beale, G., Edmondson, R. J., and Curtin, N. J.
- Subjects
ATAXIA telangiectasia ,OVARIAN cancer ,BREAST cancer ,GENETIC recombination ,DNA repair ,CELL-mediated cytotoxicity ,CISPLATIN ,ANTINEOPLASTIC agents ,HETEROCYCLIC compounds ,ORGANIC compounds ,ANIMAL experimentation ,BREAST tumors ,CELL cycle ,CELL lines ,COMPARATIVE studies ,DNA ,DRUG design ,CLINICAL drug trials ,LEUKEMIA ,RESEARCH methodology ,MEDICAL cooperation ,MICE ,ONCOGENES ,OVARIAN tumors ,PROTEIN kinases ,RESEARCH ,RESEARCH funding ,TRANSFERASES ,EVALUATION research ,CELL cycle proteins ,CHEMICAL inhibitors ,THERAPEUTICS - Abstract
Background: The ataxia telangiectasia mutated and Rad3-related kinase (ATR) has a key role in the signalling of stalled replication forks and DNA damage to cell cycle checkpoints and DNA repair. It has long been recognised as an important target for cancer therapy but inhibitors have proved elusive. As NU6027, originally developed as a CDK2 inhibitor, potentiated cisplatin in a CDK2-independent manner we postulated that it may inhibit ATR.Methods: Cellular ATR kinase activity was determined by CHK1 phosphorylation in human fibroblasts with inducible dominant-negative ATR-kinase dead expression and human breast cancer MCF7 cells. Cell cycle effects and chemo- and radiopotentiation by NU6027 were determined in MCF7 cells and the role of mismatch repair and p53 was determined in isogenically matched ovarian cancer A2780 cells.Results: NU6027 is a potent inhibitor of cellular ATR activity (IC(50)=6.7 μM) and enhanced hydroxyurea and cisplatin cytotoxicity in an ATR-dependent manner. NU6027 attenuated G2/M arrest following DNA damage, inhibited RAD51 focus formation and increased the cytotoxicity of the major classes of DNA-damaging anticancer cytotoxic therapy but not the antimitotic, paclitaxel. In A2780 cells sensitisation to cisplatin was greatest in cells with functional p53 and mismatch repair (MMR) and sensitisation to temozolomide was greatest in p53 mutant cells with functional MMR. Importantly, NU6027 was synthetically lethal when DNA single-strand break repair is impaired either through poly(ADP-ribose) polymerase (PARP) inhibition or defects in XRCC1.Conclusion: NU6027 inhibits ATR, impairing G2/M arrest and homologous recombination thus increasing sensitivity to DNA-damaging agents and PARP inhibitors. It provides proof of concept data for clinical development of ATR inhibitors. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
24. Exploiting Honokiol-induced ER stress CHOP activation inhibits the growth and metastasis of melanoma by suppressing the MITF and β-catenin pathways.
- Author
-
Chiu, Chien-Shan, Tsai, Cheng-Han, Hsieh, Ming-Shun, Tsai, Shih-Chuan, Jan, Yee-Jee, Lin, Wan-Yu, Lai, De-Wei, Wu, Sheng-Mao, Hsing, Hsiang-Yuan, Arbiser, Jack L, and Sheu, Meei-Ling
- Subjects
- *
PROTEIN metabolism , *ANIMAL experimentation , *ANTINEOPLASTIC agents , *BIPHENYL compounds , *CELL lines , *CELL physiology , *CELL motility , *CELLULAR signal transduction , *CYTOSKELETAL proteins , *GENES , *LIGNANS , *MELANOMA , *MICE , *PROTEINS , *PROTEOLYTIC enzymes , *SKIN tumors , *TRANSFERASES , *PERITONEUM tumors , *PHARMACODYNAMICS - Abstract
There is increasing global incidence of highly metastatic melanoma and therapeutic strategies like those focusing on the downstream beta-catenin/MITF axis of invading melanoma cells are urgently needed. Targeting endoplasmic reticulum (ER) stress can promote cancer cell death and inhibit epithelial mesenchymal transition (EMT) in metastatic tumors. This study aimed to determine if Honokiol could promote ER stress-dependent apoptosis and regulate metastatic melanoma. The therapeutic efficacy of Honokiol was assessed using the highly metastatic melanoma xenograft mouse model for peritoneal metastasis and evaluated by computed tomography imaging. The ER stress marker, Calpain-10, delineated a novel proteolytic cleavage enzyme, while CHOP/GADD153-regulated apoptosis was used for gene silencing to determine the role of the β-catenin/MITF axis in melanoma cells. The results showed that Honokiol effectively decreased peritoneal dissemination and organ metastasis via ER stress activation and EMT marker inhibition. Knockdown Calpain-10 or CHOP/GADD153 blocked all of the biological effects in Honokiol-induced β-catenin/MITF cleavage, ERSE or TCF/LEF luciferase activity, and β-catenin kinase activity. These findings suggest that Honokiol can significantly thwart the progression of highly metastatic melanoma using the β-catenin/MITF axis via prompt Calpain-10 and CHOP/GADD153 regulated cascades. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.
- Author
-
Tse, K-F, Mukherjee, G, and Small, D
- Subjects
ACUTE myeloid leukemia ,CELL receptors ,PROTEIN metabolism ,TYROSINE metabolism ,ANIMAL experimentation ,CELLULAR signal transduction ,COMPARATIVE studies ,DNA probes ,RESEARCH methodology ,MEDICAL cooperation ,MICE ,NUCLEOTIDES ,PHOSPHORYLATION ,RECOMBINANT proteins ,RESEARCH ,TRANSFERASES ,EVALUATION research ,NEOPLASTIC cell transformation - Abstract
Aberrant expression of FLT3 has been found in most cases of B-lineage ALL and AML, and subsets of T cell ALL, CML in blast crisis and CLL. In 20% of patients with AML the receptor has small internal tandem duplications of the juxtamembrane region which appear to contitutively activate the receptor. To investigate whether FLT3 activation could play a role in leukemia, we generated a constitutively activated FLT3 by fusing its cytoplasmic domain to the helix-loop-helix domain of TEL in analogy to the fusion that occurs with TEL-PDGFR in CMML. In vitro translation assays demonstrated oligomerization and intrinsic tyrosine kinase activity of the TEL-FLT3 chimeric receptor. Constitutively activated TEL-FLT3 conferred IL-3 independence and long-term proliferation to transfected Ba/F3 cells. Immunoblot analyses showed that JAK 2, STAT 3, STAT 5a, STAT 5b and CBL were tyrosine-phosphorylated in TEL-FLT3 expressing Ba/F3 cells in the absence of IL-3. These data suggest a possible role for the JAK/STAT pathway in FLT3 signaling. Transplantation of TEL-FLT3 expressing Ba/F3 cells into syngeneic mice caused mortality in all mice by 3 weeks after injection. Histopathologic analysis demonstrated a massive infiltration of mononuclear cells in the liver, spleen and bone marrow. The mimicking of naturally occurring TEL fusions provides an approach to assess aspects of the biology of activated FLT3, or other receptor-type tyrosine kinases (RTKs) in leukemic transformation. [ABSTRACT FROM AUTHOR]
- Published
- 2000
- Full Text
- View/download PDF
26. AKT2 Loss Impairs BRAF-Mutant Melanoma Metastasis.
- Author
-
McRee, Siobhan K., Bayer, Abraham L., Pietruska, Jodie, Tsichlis, Philip N., and Hinds, Philip W.
- Subjects
DISEASE progression ,GENETIC mutation ,MELANOMA ,ONCOGENES ,ANIMAL experimentation ,CANCER invasiveness ,METASTASIS ,ANTINEOPLASTIC agents ,CELL motility ,CELLULAR signal transduction ,TRANSFERASES ,CELL migration inhibition ,CELL proliferation ,RESEARCH funding ,MICE ,PHARMACODYNAMICS - Abstract
Simple Summary: Skin cancer, such as melanoma, is often treatable but becomes deadly when it expands to other places in the body, a process called metastasis. While many current drugs target melanoma tumor growth, no drugs yet exist to specifically prevent metastasis. Improving treatment outcomes, therefore, will require an understanding of the molecular mechanisms leading to metastasis. The AKT family of proteins are important regulators of cellular growth and signaling, which play differing roles in cancer. This work sought to study each of the AKT isoforms and their contributions to melanoma cell migration and metastasis. We found that AKT2 specifically regulates melanoma cell metastasis through effects on metabolism and melanoma cell properties, while AKT1 is involved in cellular proliferation and growth. This study suggests that specifically targeting AKT2 and AKT1 represents novel therapeutic strategies for different-stage melanoma patients. Despite recent advances in treatment, melanoma remains the deadliest form of skin cancer due to its highly metastatic nature. Melanomas harboring oncogenic BRAF
V600E mutations combined with PTEN loss exhibit unrestrained PI3K/AKT signaling and increased invasiveness. However, the contribution of different AKT isoforms to melanoma initiation, progression, and metastasis has not been comprehensively explored, and questions remain about whether individual isoforms play distinct or redundant roles in each step. We investigate the contribution of individual AKT isoforms to melanoma initiation using a novel mouse model of AKT isoform-specific loss in a murine melanoma model, and we investigate tumor progression, maintenance, and metastasis among a panel of human metastatic melanoma cell lines using AKT isoform-specific knockdown studies. We elucidate that AKT2 is dispensable for primary tumor formation but promotes migration and invasion in vitro and metastatic seeding in vivo, whereas AKT1 is uniquely important for melanoma initiation and cell proliferation. We propose a mechanism whereby the inhibition of AKT2 impairs glycolysis and reduces an EMT-related gene expression signature in PTEN-null BRAF-mutant human melanoma cells to limit metastatic spread. Our data suggest that the elucidation of AKT2-specific functions in metastasis might inform therapeutic strategies to improve treatment options for melanoma patients. [ABSTRACT FROM AUTHOR]- Published
- 2023
- Full Text
- View/download PDF
27. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
- Author
-
Lu, Jiaxiong, Guan, Shan, Zhao, Yanling, Yu, Yang, Woodfield, Sarah E., Zhang, Huiyuan, Yang, Kristine L., Bieerkehazhi, Shayahati, Qi, Lin, Li, Xiaonan, Gu, Jerry, Xu, Xin, Jin, Jingling, Muscal, Jodi A., Yang, Tianshu, Xu, Guo-Tong, and Yang, Jianhua
- Subjects
- *
ANAPLASTIC lymphoma kinase , *APOPTOSIS , *NEUROBLASTOMA , *TUMOR growth , *LABORATORY mice , *ANIMAL experimentation , *ANTHROPOMETRY , *ANTINEOPLASTIC agents , *CELL lines , *CELL physiology , *CELLULAR signal transduction , *DISEASE susceptibility , *DOXORUBICIN , *DOSE-effect relationship in pharmacology , *HETEROCYCLIC compounds , *MICE , *GENETIC mutation , *PHOSPHOTRANSFERASES , *PIPERIDINE , *RESEARCH funding , *TIME , *TRANSFERASES , *PHENOTYPES , *PROTEIN kinase inhibitors , *PHARMACODYNAMICS - Abstract
Activating germline mutations of anaplastic lymphoma kinase (ALK) occur in most cases of hereditary neuroblastoma (NB) and the constitutively active kinase activity of ALK promotes cell proliferation and survival in NB. Therefore, ALK kinase is a potential therapeutic target for NB. In this study, we show that the novel ALK inhibitor alectinib effectively suppressed cell proliferation and induces apoptosis in NB cell lines with either wild-type ALK or mutated ALK (F1174L and D1091N) by blocking ALK-mediated PI3K/Akt/mTOR signaling. In addition, alectinib enhanced doxorubicin-induced cytotoxicity and apoptosis in NB cells. Furthermore, alectinib induced apoptosis in an orthotopic xenograft NB mouse model. Also, in the TH-MYCN transgenic mouse model, alectinib resulted in decreased tumor growth and prolonged survival time. These results indicate that alectinib may be a promising therapeutic agent for the treatment of NB. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. THY1 (CD90) Maintains the Adherens Junctions in Nasopharyngeal Carcinoma via Inhibition of SRC Activation.
- Author
-
Chen, Luo, Chau, Wai Yin, Yuen, Hei Tung, Liu, Xiao Han, Qi, Robert Zhong, Lung, Maria Li, and Lung, Hong Lok
- Subjects
NASOPHARYNX cancer ,CELL membranes ,ANIMAL experimentation ,PROTEIN kinase inhibitors ,SMALL interfering RNA ,CELL receptors ,PRECIPITIN tests ,TREATMENT failure ,MEMBRANE glycoproteins ,PROTEOMICS ,TRANSFERASES ,GENES ,RESEARCH funding ,CELL lines ,ANTIGENS ,NASOPHARYNX tumors ,MICE ,PHENOTYPES - Abstract
Simple Summary: Nasopharyngeal carcinoma (NPC) is endemic to southern China and cancer metastasis remains the main cause of treatment failures. Previously we have found THY1, a cell surface glycoprotein, inhibits the invasion of NPC cells and functions as a tumor suppressor in NPC. In the present study, we further illustrated the mechanism that contributes to the tumor suppressive function of THY1. Two binding partners of THY1, PDGF-Rβ and PTPN22, were identified, and PTPN22 represents the downstream signaling molecule of THY1 to inhibit the PDGF-Rβ–induced SRC activity. The anti-metastatic effect of SRC inhibition was subsequently validated in a mice model with administration of a SRC inhibitor that has been used in clinics for other diseases. This study opens a new window to target the SRC signaling activity which is antagonized by THY1 in NPC. We had previously shown that THY1 (CD90) is a tumor suppressor in nasopharyngeal carcinoma (NPC) and that its down-regulation and loss of expression are associated with tumor metastasis, yet the mechanism leading to such effects remains unknown. In this study we show that tumor invasion could be suppressed by THY1 via adherens junction formation in a few NPC cell lines, and knockdown of THY1 would disrupt this cell-cell adhesion phenotype. Mechanistically, the activity of the SRC family kinase (SFK) member, SRC, and canonical Wnt signaling were dramatically reduced when THY1 was constitutively expressed. Previous studies by others have found that high levels of SRC activity in NPCs are associated with EMT and a poor prognosis. We hypothesized that THY1 can suppress tumor invasion in NPC via inhibition of SRC. By gene silencing of SRC, we found that the in vitro NPC cell invasion was significantly reduced and adherens junctions were restored. Through proteomic analysis, we identified that platelet-derived growth factor receptor β (PDGF-Rβ) and protein tyrosine phosphatase nonreceptor type 22 (PTPN22) are novel and potential binding partners of THY1, which were subsequently verified by co-immunoprecipitation (co-IP) analysis. The ligand of PDGF-Rβ (PDGF-BB) could highly induce SRC activation and NPC cell invasion, which could be almost completely suppressed by THY1 expression. On the other hand, the PTPN22 siRNA could enhance both the SRC activities and the cell invasion and could also disrupt the adherens junctions in the THY1-expressing NPC cells; the original THY1-induced phenotypes were reverted when the PTPN22 expression was reduced. Together, our results identified that PTPN22 is essential for THY1 to suppress cell invasion and SRC activity, maintain tight adherens junctions, and prevent NPC metastasis. These results suggested that PDGF-Rβ and SRC can be used as drug targets for suppressing NPC metastasis. Indeed, our in vivo assay using the SRC inhibitor KX2-391, clearly showed that inhibition of SRC signaling can prevent the metastasis of NPC, indicating that targeting SRC can be a promising approach to control the NPC progression. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. HULC targets the IGF1R-PI3K-AKT axis in trans to promote breast cancer metastasis and cisplatin resistance.
- Author
-
Zhou, Lei, Li, Hui, Sun, Tingge, Wen, Xue, Niu, Chao, Li, Min, Li, Wei, Hoffman, Andrew R., Hu, Ji-Fan, and Cui, Jiuwei
- Subjects
- *
RNA metabolism , *PROTEIN metabolism , *SOMATOMEDIN , *CHROMOSOMES , *PHOSPHOTRANSFERASES , *RNA , *CANCER relapse , *CELL physiology , *APOPTOSIS , *TRANSFERASES , *GENES , *CISPLATIN , *CELL lines , *MICE , *ANIMALS - Abstract
Insulin-like growth factor I receptor (IGF1R) is frequently upregulated in breast cancer. Due to its intrinsic tyrosine kinase activity, aberrant activation of the IGF1R signaling axis may enhance tumor cell proliferation and cancer stemness, causing tumor relapse, metastasis and resistance to chemotherapy. We utilized a chromatin RNA in situ reverse transcription (CRIST) approach to characterize molecular factors that regulate the IGF1R network. We identified lncRNA HULC (Highly Upregulated in Liver Cancer) as a key trans-regulator of IGF1R in breast cancer cells. Loss of HULC suppressed the expression of IGF1R and the activation of its downstream PI3K/AKT pathway, while HULC overexpression activated the axis in breast cancer cells. Using a transcription-associated trap (RAT) assay, we demonstrated that HULC functioned as a nuclear lncRNA and epigenetically activated IGF1R by directly binding to the intragenic regulatory elements of the gene, orchestrating intrachromosomal interactions, and promoting histone H3K9 acetylation. The activated HULC-IGF1R/PI3K/AKT pathway mediated tumor resistance to cisplatin through the increased expression of cancer stemness markers, including NANOG, SOX2, OCT4, CD44 and ALDH1A1. In immunodeficient mice, stimulation of the HULC-IGF1R pathway promoted tumor metastasis. These data suggest that HULC may be a new epigenetic target for IGF1R axis-targeted therapeutic intervention. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor.
- Author
-
Park, Seong Ji, Choi, Yu Sun, Lee, Seungkoo, Lee, Young Jae, Hong, Suntaek, Han, Sanghwa, and Kim, Byung-Chul
- Subjects
- *
TRANSFORMING growth factors , *LUNG cancer , *CANCER cells , *METASTASIS , *CELLULAR signal transduction , *ADENOSINE triphosphate metabolism , *AMINES , *ANIMAL experimentation , *ANIMALS , *ANTINEOPLASTIC agents , *BINDING sites , *CANCER invasiveness , *CARRIER proteins , *CELL receptors , *CELL motility , *COMPUTER simulation , *DOSE-effect relationship in pharmacology , *GENES , *GENETIC techniques , *GROWTH factors , *LUNG tumors , *MICE , *TRANSFERASES , *INDOLE compounds , *PROTEIN kinase inhibitors , *PHARMACODYNAMICS - Abstract
Transforming growth factor-β1 (TGF-β1) promotes tumor metastasis by inducing an epithelial-to-mesenchymal transition (EMT) in cancer cells. In this study, we investigated the effects of BIX02189 and XMD8-92, pharmacologic inhibitors of the MEK5 [mitogen-activated protein kinase/extracellular-signal-regulated kinase (ERK)5] signaling pathway, on the EMT and migration of cancer cells induced by TGF-β1. In human A549 lung cancer cells, TGF-β1-induced EMT, cell motility, and expression of matrix metalloproteinase-2 were completely inhibited by BIX02189, but not by XMD8-92 or small interference RNAs specific to MEK5 and ERK5. Interestingly, BIX02189 strongly blocked the activation of TGF-β1 signaling components, and this inhibitory effect was not reproduced by MEK5 inhibition. Molecular docking simulation and kinase assays revealed that BIX02189 binds directly to the ATP-binding site of the TGF-β receptor type I (TβRI) and suppresses its kinase activity. Finally, the anti-metastatic effect of BIX02189 was validated in a TβRI-derived A549 xenograft mouse model. Collectively, these findings newly characterize BIX02189 as a potent inhibitor of TβRI that can block the tumor metastatic activity of TGF-β1. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
31. Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
- Author
-
Liao, Jie, Hwang, Sung Hee, Li, Haonan, Yang, Yihe, Yang, Jun, Wecksler, Aaron T., Liu, Jun-Yan, Hammock, Bruce D., and Yang, Guang-Yu
- Subjects
- *
PANCREATIC cancer treatment , *TUMOR growth , *RAF genes , *EPOXIDE hydrolase , *CELLULAR signal transduction , *WESTERN immunoblotting , *ANIMAL experimentation , *ANTHROPOMETRY , *ANTI-infective agents , *ANTINEOPLASTIC agents , *CELL lines , *CELL physiology , *COMPARATIVE studies , *DISEASE susceptibility , *DOSE-effect relationship in pharmacology , *HYDROLASES , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *GENETIC mutation , *ONCOGENES , *ORAL drug administration , *PANCREATIC tumors , *PHOSPHORYLATION , *RESEARCH , *RESEARCH funding , *TRANSFERASES , *UNSATURATED fatty acids , *UREA , *VITAMIN B complex , *PHENOTYPES , *EVALUATION research , *DUCTAL carcinoma , *PROTEIN kinase inhibitors , *CHEMICAL inhibitors , *PHARMACODYNAMICS - Abstract
Mutant Kras and chronic pancreatitis are the most common pathological events involved in human pancreatic cancer. It has been demonstrated that c-Raf is responsible for transmitting signals from mutant Ras to its downstream signals including MEK-ERK and for initiating carcinogenesis. The soluble epoxide hydrolase (sEH), a pro-inflammatory enzyme, generally inactivates anti-inflammatory and anti-pain epoxyeicosatrienoic acids (EETs). Herein, we have synthesized a novel compound of trans-4-{4-[3-(4-chloro-3-trifluoromethyl-phenyl)-ureido]-cyclohexyloxy}-pyridine-2-carboxylic acid methylamide (t-CUPM) via modifying the central phenyl ring of sorafenib and confirmed its dual inhibition of sEH and c-Raf by recombinant kinase activity assay. Pharmacokinetic analysis revealed that oral dosing of t-CUPM resulted in higher blood levels than that of sorafenib throughout the complete time course (48 h). The effect of t-CUPM on the inhibition of mutant Kras(G12D)-initiated murine pancreatic cancer cell growth was determined using the mouse pancreatic carcinoma cell model obtained from LSL-Kras(G12D)/Pdx1-Cre mice and showed that t-CUPM significantly inhibited this murine pancreatic carcinoma cell growth both in vitro and in mice in vivo. Inhibition of mutant Kras-transmitted phosphorylations of cRAF/MEK/ERK was demonstrated in these pancreatic cancer cells using Western blot assay and immunohistochemical approach. Modulation of oxylipin profile, particularly increased EETs/DHET ratio by sEH inhibition, was observed in mice treated with t-CUPM. These results indicate that t-CUPM is a highly potential agent to treat pancreatic cancer via simultaneously targeting c-Raf and sEH. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
32. Hepatic mTORC2 Signaling Facilitates Acute Glucagon Receptor Enhancement of Insulin-Stimulated Glucose Homeostasis in Mice.
- Author
-
Kim, Teayoun, Nason, Shelly, Antipenko, Jessica, Finan, Brian, Shalev, Anath, DiMarchi, Richard, and Habegger, Kirk M.
- Subjects
GLUCOSE metabolism ,GLUCOSE intolerance ,HOMEOSTASIS ,HYPERGLYCEMIA ,LIVER ,CELL receptors ,INSULIN ,TRANSFERASES ,RESEARCH funding ,INSULIN resistance ,ANIMALS ,MICE - Abstract
Long-term glucagon receptor (GCGR) agonism is associated with hyperglycemia and glucose intolerance, while acute GCGR agonism enhances whole-body insulin sensitivity and hepatic AKTSer473 phosphorylation. These divergent effects establish a critical gap in knowledge surrounding GCGR action. mTOR complex 2 (mTORC2) is composed of seven proteins, including RICTOR, which dictates substrate binding and allows for targeting of AKTSer473. We used a liver-specific Rictor knockout mouse (RictorΔLiver) to investigate whether mTORC2 is necessary for insulin receptor (INSR) and GCGR cross talk. RictorΔLiver mice were characterized by impaired AKT signaling and glucose intolerance. Intriguingly, RictorΔLiver mice were also resistant to GCGR-stimulated hyperglycemia. Consistent with our prior report, GCGR agonism increased glucose infusion rate and suppressed hepatic glucose production during hyperinsulinemic-euglycemic clamp of control animals. However, these benefits to insulin sensitivity were ablated in RictorΔLiver mice. We observed diminished AKTSer473 and GSK3α/βSer21/9 phosphorylation in RictorΔLiver mice, whereas phosphorylation of AKTThr308 was unaltered in livers from clamped mice. These signaling effects were replicated in primary hepatocytes isolated from RictorΔLiver and littermate control mice, confirming cell-autonomous cross talk between GCGR and INSR pathways. In summary, our study reveals the necessity of RICTOR, and thus mTORC2, in GCGR-mediated enhancement of liver and whole-body insulin action. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
33. Chondroprotective effects of CDK4/6 inhibition via enhanced ubiquitin-dependent degradation of JUN in synovial fibroblasts.
- Author
-
Hosoya, Tadashi, Saito, Tetsuya, Baba, Hiroyuki, Tanaka, Nao, Noda, Seiji, Komiya, Youji, Tagawa, Yasuhiro, Yamamoto, Akio, Mizoguchi, Fumitaka, Kawahata, Kimito, Miyasaka, Nobuyuki, Kohsaka, Hitoshi, and Yasuda, Shinsuke
- Subjects
PROTEIN metabolism ,COLLAGEN ,BIOLOGICAL models ,SYNOVIAL membranes ,FIBROBLASTS ,SEQUENCE analysis ,ANIMAL experimentation ,WESTERN immunoblotting ,MATRIX metalloproteinases ,GENE expression ,RHEUMATOID arthritis ,TRANSFERASES ,ENZYME-linked immunosorbent assay ,POLYMERASE chain reaction ,MICE - Abstract
Objective Targeting synovial fibroblasts (SF) using a cyclin-dependent kinase (CDK) 4/6 inhibitor (CDKI) could be a potent therapy for RA via inhibition of proliferation and MMP-3 production. This study was designed to elucidate the mechanism of chondroprotective effects on SFs by CDK 4/6 inhibition. Methods CDK4/6 activity was inhibited using CDKI treatment or enhanced by adenoviral gene transduction. Chondroprotective effects were evaluated using a collagen-induced arthritis model (CIA). Gene and protein expression were evaluated with quantitative PCR, ELISA and Western blotting. The binding of nuclear extracts to DNA was assessed with an electrophoresis mobility shift assay. RNA-Seq was performed to identify gene sets affected by CDKI treatment. Results CDKI attenuated cartilage destruction and MMP-3 production in CIA. In RASFs, CDKI impaired the binding of AP-1 components to DNA and inhibited the production of MMP-1 and MMP-3, which contain the AP-1 binding sequence in their promoter. CDK4/6 protected JUN from proteasome-dependent degradation by inhibiting ubiquitination. The RNA-Seq analysis identified CDKI-sensitive inflammatory genes, which were associated with the pathway of RA-associated genes, cytokine-cytokine receptor interaction and IL-17 signalling. Notably, the AP-1 motif was enriched in these genes. Conclusion The mechanism of chondroprotective effects by CDK4/6 inhibition was achieved by the attenuation of AP-1 transcriptional activity via the impaired stability of JUN. Because the pharmacologic inhibition of CDK4/6 has been established as tolerable in cancer treatment, it could also be beneficial in patients with RA due to its chondroprotective and anti-inflammatory effects. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models.
- Author
-
Fang, Douglas D., Tao, Ran, Wang, Guangfeng, Li, Yuanbao, Zhang, Kaixiang, Xu, Chunhua, Zhai, Guoqin, Wang, Qixin, Wang, Jingwen, Tang, Chunyang, Min, Ping, Xiong, Dengkun, Chen, Jianyong, Wang, Shaomeng, Yang, Dajun, and Zhai, Yifan
- Subjects
LUNG cancer ,PROTEINS ,OVARIAN tumors ,PROTEIN kinase inhibitors ,ANIMAL experimentation ,LUNG tumors ,CELL receptors ,TRANSFERASES ,PROTEIN-tyrosine kinases ,MICE ,PHARMACODYNAMICS - Abstract
Background: Tyrosine kinase inhibitors (TKIs) are mainstays of cancer treatment. However, their clinical benefits are often constrained by acquired resistance. To overcome such outcomes, we have rationally engineered APG-2449 as a novel multikinase inhibitor that is highly potent against oncogenic alterations of anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 receptor tyrosine kinase (ROS1), and focal adhesion kinase (FAK). Here we present the preclinical evaluation of APG-2449, which exhibits antiproliferative activity in cells carrying ALK fusion or secondary mutations.Methods: KINOMEscan® and LANCE TR-FRET were used to characterize targets and selectivity of APG-2449. Water-soluble tetrazolium salt (WST-8) viability assay and xenograft tumorigenicity were employed to evaluate therapeutic efficacy of monotherapy or drug combination in preclinical models of solid tumors. Western blot, pharmacokinetic, and flow cytometry analyses, as well as RNA sequencing were used to explore pharmacokinetic-pharmacodynamic correlations and the mechanism of actions driving drug combination synergy.Results: In mice bearing wild-type or ALK/ROS1-mutant non-small-cell lung cancer (NSCLC), APG-2449 demonstrates potent antitumor activity, with correlations between pharmacokinetics and pharmacodynamics in vivo. Through FAK inhibition, APG-2449 sensitizes ovarian xenograft tumors to paclitaxel by reducing CD44+ and aldehyde dehydrogenase 1-positive (ALDH1+) cancer stem cell populations, including ovarian tumors insensitive to carboplatin. In epidermal growth factor receptor (EGFR)-mutated NSCLC xenograft models, APG-2449 enhances EGFR TKI-induced tumor growth inhibition, while the ternary combination of APG-2449 with EGFR (osimertinib) and mitogen-activated extracellular signal-regulated kinase (MEK; trametinib) inhibitors overcomes osimertinib resistance. Mechanistically, phosphorylation of ALK, ROS1, and FAK, as well as their downstream components, is effectively inhibited by APG-2449.Conclusions: Taken together, our studies demonstrate that APG-2449 exerts potent and durable antitumor activity in human NSCLC and ovarian tumor models when administered alone or in combination with other therapies. A phase 1 clinical trial has been initiated to evaluate the safety and preliminary efficacy of APG-2449 in patients with advanced solid tumors, including ALK+ NSCLC refractory to earlier-generation ALK inhibitors.Trial Registration: Clinicaltrial.gov registration: NCT03917043 (date of first registration, 16/04/2019) and Chinese clinical trial registration: CTR20190468 (date of first registration, 09/04/2019). [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
35. Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3.
- Author
-
Lu, Hao, Weng, Xiang-qin, Sheng, Yan, Wu, Jing, Xi, Hui-min, and Cai, Xun
- Subjects
GENETIC mutation ,PROTEIN kinase inhibitors ,TRETINOIN ,ALKALOIDS ,TRANSFERASES ,RESEARCH funding ,ANIMALS ,MICE ,PHARMACODYNAMICS - Abstract
Background: Midostaurin combined with chemotherapy is currently used to treat newly diagnosed acute myeloid leukemia (AML) patients with FMS-like tyrosine kinase 3 (FLT3)-mutations. However, midostaurin acts as an antagonist to some chemotherapeutic agents in leukemia cell lines without FLT3 mutations. All-trans retinoic acid (ATRA) induces apoptosis when used in combination with midostaurin in FLT3-mutated AML cells. This combination has been shown to be safe in AML patients. However, the effect of this combination has not been investigated in AML without FLT3 mutations.Methods: Cell proliferation was assessed by a cell counting assay. Cell death was evaluated by cell viability and Annexin-V assays. Cell differentiation was assessed by CD11b expression profiling and morphological analysis. To explore the underlying mechanisms, we studied the role of caspase3/7, Lyn, Fgr, Hck, RAF, MEK, ERK, AKT, PU.1, CCAAT/enhancer binding protein β (C/EBPβ) and C/EBPε by Western blot analysis and immunoprecipitation assays. Antitumor activity was also confirmed in mouse xenograft models established with AML cells.Results: In this study, 0.1 - 0.25 μM midostaurin (mido(L)) combined with ATRA induced differentiation while 0.25 - 0.5 μM midostaurin (mido(H)) combined with ATRA triggered apoptosis in some AML cell lines without FLT3-mutations. Midostaurin combined with ATRA (mido-ATRA) also exhibited antitumor activity in mouse xenograft models established with AML cells. Mechanistically, mido(H)-ATRA-induced apoptosis was dependent on caspase-3/7. Mido(L)-ATRA inhibited Akt activation which was associated with decreased activity of Lyn/Fgr/Hck, resulted in dephosphorylation of RAF S259, activated RAF/MEK/ERK, along with upregulating the protein levels of C/EBPβ, C/EBPε and PU.1. A MEK specific inhibitor was observed to suppress mido(L)-ATRA-induced increases in the protein levels of C/EBPs and PU.1 and mido(L)-ATRA-induced differentiation. Furthermore, inhibition of Akt activity promoted mido(L)-ATRA-induced downregulation of RAF S259 phosphorylation and mido(L)-ATRA-induced differentiation. Therefore, Lyn/Fgr/Hck-associated Akt inhibition activated RAF/MEK/ERK and controlled mido(L)-ATRA-induced differentiation by upregulation of C/EBPs and PU.1. Mido(L)-ATRA also promoted assembly of the signalosome, which may facilitate RAF activation.Conclusions: Midostaurin combined with ATRA exerts antitumor activity against AML with wild-type FLT3 mutations in vitro and in vivo. These findings may provide novel therapeutic strategies for some AML patients without FLT3 mutations and imply a new target of midostaurin. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
36. Combined Targeting of AKT and mTOR Inhibits Tumor Formation of EpCAM + and CD90 + Human Hepatocellular Carcinoma Cells in an Orthotopic Mouse Model.
- Author
-
Moustafa, Mohamed, Dähling, Katarzyna-Krystyna, Günther, Armin, Riebandt, Leonie, Smit, Daniel J., Riecken, Kristoffer, Schröder, Carina, Zhuang, Ruimeng, Krech, Till, Kriegs, Malte, Fehse, Boris, Izbicki, Jakob R., Fischer, Lutz, Nashan, Björn, Li, Jun, and Jücker, Manfred
- Subjects
IN vitro studies ,XENOGRAFTS ,ANIMAL experimentation ,SIGNAL peptides ,TRANSFERASES ,CELL adhesion molecules ,CELL proliferation ,HEPATOCELLULAR carcinoma ,MICE ,DRUG resistance in cancer cells - Abstract
Simple Summary: Cancer stem cells are a distinct tumor subpopulation associated with poor outcome. The epithelial cell adhesion molecule (EpCAM) and Thy-1 cell surface antigen (CD90) have been implicated as cancer stem cell (CSC) markers in hepatocellular carcinoma (HCC). Eradication of those CSCs is of high importance with respect to the outcome of treatment. We aimed to verify the impact of targeting HCC cells expressing the CSC marker CD90 and EpCAM with combined therapy of AKT and mTOR inhibitors. Our data demonstrated that combined targeting of AKT and mTOR is highly synergistic in vitro but leads to treatment resistance of xenograft tumors in an orthotopic mouse model in vivo. The development of resistance was observed in large numbers of MK2206/RAD001 treated cells. Restoration of phosphorylated AKT was observed in most tumors during AKT/mTOR therapy underlining the importance of restored AKT signaling as a resistance mechanism. Further work is required to verify the molecular mechanisms of HCC treatment resistance. The epithelial cell adhesion molecule (EpCAM) and Thy-1 cell surface antigen (CD90) have been implicated as cancer stem cell (CSC) markers in hepatocellular carcinoma (HCC). Expression of EpCAM and CD90 on HCC cells is associated with increased tumorigenicity, metastasis and poor prognosis. In this study, we demonstrate that combined treatment with AKT and mTOR inhibitors—i.e., MK2206 and RAD001—results in a synergistic reduction in proliferation of EpCAM
+ and CD90+ HCC cells cultured either as adherent cells or as tumoroids in vitro. In addition, tumor growth was reduced by combined treatment with AKT and mTOR inhibitors in an orthotopic xenograft mouse model of an EpCAM+ HCC cell line (Huh7) and primary patient-derived EpCAM+ HCC cells (HCC1) as well as a CD90+ HCC-related cell line (SK-HEP1) in vivo. However, during AKT/mTOR treatment, outgrowth of therapy-resistant tumors was observed in all mice analyzed within a few weeks. Resistance was associated in most cases with restoration of AKT signaling in the tumors, intrahepatic metastases and distant metastases. In addition, an upregulation of the p38 MAPK pathway was identified in the AKT/mTOR inhibitor-resistant tumor cells by kinome profiling. The development of resistant cells during AKT/mTOR therapy was further analyzed by red-green-blue (RGB) marking of HCC cells, which revealed an outgrowth of a large number of Huh7 cells over a period of 6 months. In summary, our data demonstrate that combined treatment with AKT and mTOR inhibitors exhibits synergistic effects on proliferation of EpCAM+ as well as CD90+ HCC cells in vitro. However, the fast development of large numbers of resistant clones under AKT/mTOR therapy observed in vitro and in the orthotopic xenotransplantation mouse model in vivo strongly suggests that this therapy alone will not be sufficient to eliminate EpCAM+ or CD90+ cancer stem cells from HCC patients. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
37. LncRNA NEAT1 facilitates glioma progression via stabilizing PGK1.
- Author
-
Liang, Jingshan, Liu, Changtao, Xu, Dezhi, Xie, Kang, and Li, Aimin
- Subjects
GLIOMAS ,LINCRNA ,TUMOR growth ,GLYCOLYSIS ,OVERALL survival ,RNA metabolism ,RESEARCH ,ANIMAL experimentation ,RESEARCH methodology ,RNA ,CELL physiology ,EVALUATION research ,COMPARATIVE studies ,GENES ,TRANSFERASES ,CELL lines ,MICE - Abstract
Background: Long noncoding RNA NEAT1 has been implicated in glioma progression. However, the effect of NEAT1 on glycolysis of glioma cell and the potential mechanism remain unclear.Methods: In vitro experiments, including CCK-8, colony formation, ECAR, and lactate detection assays were performed to evaluate the effect of NEAT1 on proliferation and glycolysis of glioma cell. RNA pulldown and RIP assays were performed to identify the interaction between NEAT1 and PGK1. Truncated mutation of NEAT1 and PGK1 was used to confirm the specific interactive domains between NEAT1 and PGK1. Animal studies were performed to analyze the effect of NEAT1/PGK1 on glioma progression.Results: NEAT1 knockdown significantly suppressed the proliferation and glycolysis of glioma cells. NEAT1 could specifically interact with PGK1, which promotes PGK1 stability. Hairpin A of NEAT1 is essential for interaction with M1 domain of PGK1. Depletion of NEAT1 markedly inhibited tumor growth in mice, while PGK1 could reverse this effect. Higher expression of NEAT1 was associated with poor overall survival of GBM patients.Conclusions: NEAT1 over expression promotes glioma progression through stabilizing PGK1. NEAT1/PGK1 axis is a candidate therapeutic target for glioma treatment. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
38. XPC silencing in normal human keratinocytes triggers metabolic alterations that drive the formation of squamous cell carcinomas.
- Author
-
Rezvani, Hamid Reza, Kim, Arianna L., Rossignol, Rodrigue, Ali, Nsrein, Daly, Meaghan, Mahfouf, Walid, Bellance, Nadege, Taieb, Alain, de Verneuil, Hubert, Mazurier, Frédéric, Bickers, David A., Bellance, Nadège, Taïeb, Alain, Mazurier, Frédéric, and Bickers, David R
- Subjects
- *
DNA , *CARCINOGENESIS , *CANCER cells , *BIOENERGETICS , *GENOMICS , *PROTEIN kinases , *KERATINOCYTES , *DNA metabolism , *REACTIVE oxygen species , *ANIMAL experimentation , *BIOLOGICAL models , *CELL physiology , *COMPARATIVE studies , *ENERGY metabolism , *GENES , *GENETIC techniques , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *MITOCHONDRIA , *GENETIC mutation , *OXIDOREDUCTASES , *RESEARCH , *SKIN tumors , *SQUAMOUS cell carcinoma , *TRANSFERASES , *XENOGRAFTS , *DNA-binding proteins , *EVALUATION research , *NEOPLASTIC cell transformation , *CHEMICAL inhibitors , *TRANSPLANTATION of organs, tissues, etc. - Abstract
DNA damage is a well-known initiator of tumorigenesis. Studies have shown that most cancer cells rely on aerobic glycolysis for their bioenergetics. We sought to identify a molecular link between genomic mutations and metabolic alterations in neoplastic transformation. We took advantage of the intrinsic genomic instability arising in xeroderma pigmentosum C (XPC). The XPC protein plays a key role in recognizing DNA damage in nucleotide excision repair, and patients with XPC deficiency have increased incidence of skin cancer and other malignancies. In cultured human keratinocytes, we showed that lentivirus-mediated knockdown of XPC reduced mitochondrial oxidative phosphorylation and increased glycolysis, recapitulating cancer cell metabolism. Accumulation of unrepaired DNA following XPC silencing increased DNA-dependent protein kinase activity, which subsequently activated AKT1 and NADPH oxidase-1 (NOX1), resulting in ROS production and accumulation of specific deletions in mitochondrial DNA (mtDNA) over time. Subcutaneous injection of XPC-deficient keratinocytes into immunodeficient mice led to squamous cell carcinoma formation, demonstrating the tumorigenic potential of transduced cells. Conversely, simultaneous knockdown of either NOX1 or AKT1 blocked the neoplastic transformation induced by XPC silencing. Our results demonstrate that genomic instability resulting from XPC silencing results in activation of AKT1 and subsequently NOX1 to induce ROS generation, mtDNA deletions, and neoplastic transformation in human keratinocytes. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
39. Molecular imaging of phosphorylation events for drug development.
- Author
-
Chan, C T, Paulmurugan, R, Reeves, R E, Solow-Cordero, D, and Gambhir, S S
- Subjects
- *
PROTEIN metabolism , *ANIMAL experimentation , *CELL lines , *COMPARATIVE studies , *DRUG design , *GENETIC techniques , *LIGHT , *MOLECULAR probes , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *GENETIC mutation , *OXIDOREDUCTASES , *PHOSPHORYLATION , *PHOSPHOTRANSFERASES , *RESEARCH , *RESEARCH funding , *TRANSFERASES , *EVALUATION research , *PROTEIN kinase inhibitors , *PHARMACODYNAMICS - Abstract
Purpose: Protein phosphorylation mediated by protein kinases controls numerous cellular processes. A genetically encoded, generalizable split firefly luciferase (FL)-assisted complementation system was developed for noninvasive monitoring phosphorylation events and efficacies of kinase inhibitors in cell culture and in small living subjects by optical bioluminescence imaging.Procedures: An Akt sensor (AST) was constructed to monitor Akt phosphorylation and the effect of different PI-3K and Akt inhibitors. Specificity of AST was determined using a non-phosphorylable mutant sensor containing an alanine substitution (ASA).Results: The PI-3K inhibitor LY294002 and Akt kinase inhibitor perifosine led to temporal- and dose-dependent increases in complemented FL activities in 293T human kidney cancer cells stably expressing AST (293T/AST) but not in 293T/ASA cells. Inhibition of endogenous Akt phosphorylation and kinase activities by perifosine also correlated with increase in complemented FL activities in 293T/AST cells but not in 293T/ASA cells. Treatment of nude mice bearing 293T/AST xenografts with perifosine led to a 2-fold increase in complemented FL activities compared to that of 293T/ASA xenografts. Our system was used to screen a small chemical library for novel modulators of Akt kinase activity.Conclusion: This generalizable approach for noninvasive monitoring of phosphorylation events will accelerate the discovery and validation of novel kinase inhibitors and modulators of phosphorylation events. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
40. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer.
- Author
-
Ciampi, Raffaele, Knauf, Jeffrey A., Kerler, Roswitha, Gandhi, Manoj, Zhu, Zhaowen, Nikiforova, Marina N., Rabes, Hartmut M., Fagin, James A., and Nikiforov, Yuri E.
- Subjects
- *
ONCOGENES , *MUTAGENS , *GENETIC mutation , *PROTEIN-tyrosine kinases , *PHOSPHOTRANSFERASES , *GENES , *RNA metabolism , *VALINE metabolism , *ANIMAL experimentation , *CARRIER proteins , *CELL lines , *CELLS , *CELLULAR signal transduction , *CHROMOSOMES , *COMPARATIVE studies , *CYTOSKELETAL proteins , *GENETICS , *HISTORY , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *NUCLEOTIDES , *PRIMATES , *PROTEINS , *RECOMBINANT proteins , *RESEARCH , *RESEARCH funding , *RNA , *THYROID gland tumors , *TIME , *TRANSFERASES , *VALINE , *EVALUATION research , *PAPILLARY carcinoma - Abstract
Genes crucial for cancer development can be mutated via various mechanisms, which may reflect the nature of the mutagen. In thyroid papillary carcinomas, mutations of genes coding for effectors along the MAPK pathway are central for transformation. BRAF point mutation is most common in sporadic tumors. By contrast, radiation-induced tumors are associated with paracentric inversions activating the receptor tyrosine kinases RET and NTRK1. We report here a rearrangement of BRAF via paracentric inversion of chromosome 7q resulting in an in-frame fusion between exons 1-8 of the AKAP9 gene and exons 9-18 of BRAF. The fusion protein contains the protein kinase domain and lacks the autoinhibitory N-terminal portion of BRAF. It has elevated kinase activity and transforms NIH3T3 cells, which provides evidence, for the first time to our knowledge, of in vivo activation of an intracellular effector along the MAPK pathway by recombination. The AKAP9-BRAF fusion was preferentially found in radiation-induced papillary carcinomas developing after a short latency, whereas BRAF point mutations were absent in this group. These data indicate that in thyroid cancer, radiation activates components of the MAPK pathway primarily through chromosomal paracentric inversions, whereas in sporadic forms of the disease, effectors along the same pathway are activated predominantly by point mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
41. A Novel Role for BRIP1/FANCJ in Neuronal Cells Health and in Resolving Oxidative Stress-Induced DNA Lesions.
- Author
-
Mani, Chinnadurai, Acharya, Ganesh, Kshirsagar, Sudhir, Vijayan, Murali, Khan, Hafiz, Reddy, P. Hemachandra, and Palle, Komaraiah
- Subjects
DNA damage ,OXYGEN consumption ,DNA helicases ,DNA structure ,CELL death ,GLUTAMIC acid ,DNA replication ,BRAIN ,PROTEINS ,NEURONS ,DNA ,ANIMAL experimentation ,CELL physiology ,OXIDATIVE stress ,TRANSFERASES ,CELL lines ,NEURODEGENERATION ,MICE - Abstract
Background: DNA damage accumulation and mitochondrial abnormalities are elevated in neurons during aging and may contribute to neurodegenerative pathologic conditions such as Alzheimer's disease. BRCA1 interacting protein 1 or BRIP1 is a 5' to 3' DNA helicase that catalyzes many abnormal DNA structures during DNA replication, gene transcription, and recombination, and contribute to genomic integrity.Objective: BRIP1 functions were reasonably well studied in DNA repair; however, there is limited data on its role and regulation during aging and neurodegenerative diseases.Methods: We used immunohistochemistry, western blot, and qRT-PCR assays to analyze the expression of BRIP1. Immunofluorescence studies were performed to study the formation of R-loops, reactive oxygen species (ROS) generation, and mitochondrial morphology. Flow cytometry and transmission electron microscopy were used to evaluate mitochondrial ROS and mitochondrial structures, respectively. Oxygen consumption rate was measured using Seahorse, and the Presto Blue™ assays were used to evaluate cell viability.Results: Our results demonstrate the expression of BRIP1 in mouse and human brain tissues and in neuronal cell lines. BRIP1 levels were elevated in the hippocampal regions of the brains, specifically in the dentate gyrus. BRIP1 downregulation in neuronal cells caused increased R-loop formation basally and in response to H2O2 treatment. Furthermore, BRIP1 deficient cells exhibited elevated levels of excitotoxicity induced by L-Glutamic acid exposure as evidenced by (mitochondrial) ROS levels, deteriorated mitochondrial health, and cell death compared to BRIP1 proficient neuronal cells.Conclusion: Overall, our results indicate an important role for BRIP1 in maintaining neuronal cell health and homeostasis by suppressing cellular oxidative stress. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
42. Nef stimulates proliferation of glomerular podocytes through activation of Src-dependent Stat3 and MAPK1,2 pathways.
- Author
-
He, John Cijiang, Husain, Mohammad, Sunamoto, Masaaki, D'Agati, Vivette D, Klotman, Mary E, Iyengar, Ravi, and Klotman, Paul E
- Subjects
- *
PROTEIN metabolism , *ANIMAL experimentation , *CARRIER proteins , *CELL division , *CELLULAR signal transduction , *COMPARATIVE studies , *KIDNEY glomerulus , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *PHOSPHORYLATION , *RESEARCH , *RESEARCH funding , *TRANSFERASES , *DNA-binding proteins , *EVALUATION research - Abstract
In collapsing focal segmental glomerulosclerosis (FSGS) of HIV-associated nephropathy (HIVAN), podocytes exhibit a high proliferation rate and loss of differentiation markers. We have found previously that the nef gene of HIV-1 is responsible for these changes. Here, we investigated the signaling pathways induced by Nef and its role in the pathogenesis of HIVAN. Using conditionally immortalized podocytes after differentiation, we found that infection of podocytes with nef increased Src kinase activity and signal transducer and activator of transcription 3 (Stat3) phosphorylation and activated the Ras-c-Raf-MAPK1,2 pathway. A dominant negative mutant of Src abolished the Nef effect, whereas inhibition of MAPK1,2 or dominant negative Stat3 reduced Nef effects partially. Reducing the expression of Nef with small interference RNA reversed the Nef effect. Mutation of Nef in the PxxP or R105R106 motifs diminished Nef signaling and the phenotypic changes in podocytes. Both phospho-MAPK1,2 and phospho-Stat3 staining increased in podocytes of kidneys from HIV-1 transgenic mice compared with their littermates and in podocytes of kidneys from HIVAN patients compared with HIV patients with non-HIVAN kidney diseases or non-HIV patients with idiopathic FSGS, classic FSGS, or minimal-change disease. These data suggest that Nef-induced activation of Stat3 and Ras-MAPK1,2 via Src-dependent pathways is responsible for podocyte proliferation and dedifferentiation, a characteristic finding in collapsing FSGS of HIVAN. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
43. Trilostane, a 3β-hydroxysteroid dehydrogenase inhibitor, suppresses growth of hepatocellular carcinoma and enhances anti-cancer effects of sorafenib.
- Author
-
Lin, Jiunn-Chang, Liu, Chien-Liang, Chang, Yuan-Ching, Cheng, Shih-Ping, Huang, Wen-Chien, Lin, Chi-Hsin, Wu, Chun-Yi, and Chen, Ming-Jen
- Subjects
DRUG efficacy ,IN vitro studies ,IN vivo studies ,XENOGRAFTS ,ANIMAL experimentation ,ANTINEOPLASTIC agents ,CANCER patients ,CELL motility ,SORAFENIB ,DRUG synergism ,DESCRIPTIVE statistics ,DOSE-effect relationship in pharmacology ,TRANSFERASES ,OXIDOREDUCTASES ,CELL lines ,HEPATOCELLULAR carcinoma ,ENZYME inhibitors ,MICE ,PHOSPHORYLATION ,PHARMACODYNAMICS ,CHEMICAL inhibitors ,EVALUATION - Abstract
Summary: Background Human 3β-hydroxysteroid dehydrogenase type 1 (HSD3B1) is an enzyme associated with steroidogenesis, however its' role in hepatocellular carcinoma (HCC) biology is unknown. Trilostane is an inhibitor of HSD3B1 and has been tested as a treatment for patients with breast cancer but has not been studied in patients with HCC. Methods and Results The expression of HSD3B1 in HCC tumors in 57 patients were examined. A total of 44 out of 57 tumors (77.2%) showed increased HSD3B1 expression. The increased HSD3B1 in tumors was significantly associated with advanced HCC. In vitro, the knockdown of HSD3B1 expression in Mahlavu HCC cells by a short hairpin RNA (shRNA) led to significant decreases in colony formation and cell migration. The suppression of clonogenicity in the HSD3B1-knockdown HCC cells was reversed by testosterone and 17β-estradiol. Trilostane-mediated inhibition of HSD3B1 in different HCC cells also caused significant inhibition of clonogenicity and cell migration. In subcutaneous HCC Mahlavu xenografts, trilostane (30 or 60 mg/kg, intraperitoneal injection) significantly inhibited tumor growth in a dose-dependent manner. Furthermore, the combination of trilostane and sorafenib significantly enhanced the inhibition of clonogenicity and xenograft growth, surpassing the effects of each drug used alone, with no documented additional toxicity to animals. HSD3B1 blockade was found to suppress the phosphorylation of extracellular signal-regulated kinase (ERK). The decreased ERK phosphorylation was reversed by testosterone or 17b-estradiol. Conclusions Trilostane significantly inhibited the growth of HCC by inhibiting HSD3B1 function and augmenting the efficacy of sorafenib. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
44. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy.
- Author
-
Yamamoto, Shimako, Yang, Guiping, Zablocki, Daniela, Liu, Jing, Hong, Chull, Kim, Song-Jung, Soler, Sandra, Odashima, Mari, Thaisz, Jill, Yehia, Ghassan, Molina, Carlos A, Yatani, Atsuko, Vatner, Dorothy E, Vatner, Stephen F, and Sadoshima, Junichi
- Subjects
- *
CELL metabolism , *HEART metabolism , *ALKALOIDS , *ANIMAL experimentation , *APOPTOSIS , *BIOCHEMISTRY , *CELL culture , *CELLS , *COMPARATIVE studies , *CORONARY disease , *ENZYME inhibitors , *GENES , *GENETICS , *CARDIAC hypertrophy , *HEART ventricles , *HETEROCYCLIC compounds , *IMMUNITY , *PHENOMENOLOGY , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *MYOCARDIAL reperfusion complications , *MYOCARDIUM , *PROTEINS , *PROTEOLYTIC enzymes , *RATS , *RESEARCH , *RESEARCH funding , *TRANSFERASES , *EVALUATION research , *DILATED cardiomyopathy , *PHARMACODYNAMICS - Abstract
Activation of mammalian sterile 20-like kinase 1 (Mst1) by genotoxic compounds is known to stimulate apoptosis in some cell types. The importance of Mst1 in cell death caused by clinically relevant pathologic stimuli is unknown, however. In this study, we show that Mst1 is a prominent myelin basic protein kinase activated by proapoptotic stimuli in cardiac myocytes and that Mst1 causes cardiac myocyte apoptosis in vitro in a kinase activity-dependent manner. In vivo, cardiac-specific overexpression of Mst1 in transgenic mice results in activation of caspases, increased apoptosis, and dilated cardiomyopathy. Surprisingly, however, Mst1 prevents compensatory cardiac myocyte elongation or hypertrophy despite increased wall stress, thereby obscuring the use of the Frank-Starling mechanism, a fundamental mechanism by which the heart maintains cardiac output in response to increased mechanical load at the single myocyte level. Furthermore, Mst1 is activated by ischemia/reperfusion in the mouse heart in vivo. Suppression of endogenous Mst1 by cardiac-specific overexpression of dominant-negative Mst1 in transgenic mice prevents myocyte death by pathologic insults. These results show that Mst1 works as both an essential initiator of apoptosis and an inhibitor of hypertrophy in cardiac myocytes, resulting in a previously unrecognized form of cardiomyopathy. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
45. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.
- Author
-
Teller, S, Krämer, D, Böhmer, S-A, Tse, K F, Small, D, Mahboobi, S, Wallrapp, C, Beckers, T, Kratz-Albers, K, Schwäble, J, Serve, H, and Böhmer, F-D
- Subjects
- *
PROTEIN metabolism , *ANIMAL experimentation , *ANTINEOPLASTIC agents , *CELL receptors , *CELLS , *CELLULAR signal transduction , *COMPARATIVE studies , *CLINICAL drug trials , *ENZYME inhibitors , *GENETIC techniques , *HEMATOPOIETIC stem cells , *INTERLEUKIN-3 , *RESEARCH methodology , *MEDICAL cooperation , *MICE , *PHOSPHORYLATION , *PLATELET-derived growth factor , *PROTEINS , *RECOMBINANT proteins , *RESEARCH , *RESEARCH funding , *STEM cells , *TRANSFERASES , *EVALUATION research , *INDOLE compounds , *CHEMICAL inhibitors , *PHARMACODYNAMICS - Abstract
Aberrant expression and activating mutations of the class III receptor tyrosine kinase Flt3 (Flk-2, STK-1) have been linked to poor prognosis in acute myeloid leukemia (AML). Inhibitors of Flt3 tyrosine kinase activity are, therefore, of interest as potential therapeutic compounds. We previously described bis(1H-2-indolyl)-1-methanones as a novel class of selective inhibitors for platelet-derived growth factor receptors (PDGFR). Several bis(1H-2-indolyl)-1-methanone derivatives, represented by the compounds D-64406 and D-65476, are also potent inhibitors of Flt3. They inhibit proliferation of TEL-Flt3-transfected BA/F3 cells with IC(50) values of 0.2-0.3 microM in the absence of IL-3 but >10 microM in the presence of IL-3. Ligand-stimulated autophosphorylation of Flt3 in EOL-1 cells and corresponding downstream activation of Akt/PKB are effectively inhibited by bis(1H-2-indolyl)-1-methanones whereas autophosphorylation of c-Kit/SCF receptor or c-Fms/CSF-1 receptor is less sensitive or insensitive, respectively. Flt3 kinase purified by different methods is potently inhibited in vitro, demonstrating a direct mechanism of inhibition. 32D cells, expressing a constitutively active Flt3 variant with internal tandem duplication are greatly sensitized to radiation-induced apoptosis in the presence of D-64406 or D-65476 in the absence but not in the presence of IL-3. Thus, bis(1H-2-indolyl)-1-methanones are potential candidates for the treatment of Flt3-driven leukemias. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
46. Pathogenic MAST3 Variants in the STK Domain Are Associated with Epilepsy.
- Author
-
Spinelli, Egidio, Christensen, Kyle R., Bryant, Emily, Schneider, Amy, Rakotomamonjy, Jennifer, Muir, Alison M., Giannelli, Jessica, Littlejohn, Rebecca O., Roeder, Elizabeth R., Schmidt, Berkley, Wilson, William G., Marco, Elysa J., Iwama, Kazuhiro, Kumada, Satoko, Pisano, Tiziana, Barba, Carmen, Vetro, Annalisa, Brilstra, Eva H., van Jaarsveld, Richard H., and Matsumoto, Naomichi
- Subjects
EPILEPSY ,NEUROLOGICAL disorders ,CORPUS callosum ,FETAL development ,COMPLEMENTARY DNA ,RESEARCH ,GENETICS ,NERVE tissue proteins ,ANIMAL experimentation ,RESEARCH methodology ,MEDICAL cooperation ,EVALUATION research ,COMPARATIVE studies ,TRANSFERASES ,RESEARCH funding ,AMINO acids ,EPITHELIAL cells ,MICE ,LONGITUDINAL method - Abstract
Objective: The MAST family of microtubule-associated serine-threonine kinases (STKs) have distinct expression patterns in the developing and mature human and mouse brain. To date, only MAST1 has been conclusively associated with neurological disease, with de novo variants in individuals with a neurodevelopmental disorder, including a mega corpus callosum.Methods: Using exome sequencing, we identify MAST3 missense variants in individuals with epilepsy. We also assess the effect of these variants on the ability of MAST3 to phosphorylate the target gene product ARPP-16 in HEK293T cells.Results: We identify de novo missense variants in the STK domain in 11 individuals, including 2 recurrent variants p.G510S (n = 5) and p.G515S (n = 3). All 11 individuals had developmental and epileptic encephalopathy, with 8 having normal development prior to seizure onset at <2 years of age. All patients developed multiple seizure types, 9 of 11 patients had seizures triggered by fever and 9 of 11 patients had drug-resistant seizures. In vitro analysis of HEK293T cells transfected with MAST3 cDNA carrying a subset of these patient-specific missense variants demonstrated variable but generally lower expression, with concomitant increased phosphorylation of the MAST3 target, ARPP-16, compared to wild-type. These findings suggest the patient-specific variants may confer MAST3 gain-of-function. Moreover, single-nuclei RNA sequencing and immunohistochemistry shows that MAST3 expression is restricted to excitatory neurons in the cortex late in prenatal development and postnatally.Interpretation: In summary, we describe MAST3 as a novel epilepsy-associated gene with a potential gain-of-function pathogenic mechanism that may be primarily restricted to excitatory neurons in the cortex. ANN NEUROL 2021;90:274-284. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
47. High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
- Author
-
Zeng, Zhihong, Ly, Charlie, Daver, Naval, Cortes, Jorge, Kantarjian, Hagop M., Andreeff, Michael, and Konopleva, Marina
- Subjects
PROGENITOR cells ,ACUTE myeloid leukemia ,KINASE inhibitors ,PROTEIN microarrays ,PROTEOMICS ,AZACITIDINE ,PROTEIN kinase inhibitors ,APOPTOSIS ,STEM cells ,TRANSFERASES ,RESEARCH funding ,CELL lines ,MICE ,ANIMALS ,PHARMACODYNAMICS - Abstract
FLT3 mutations, which are found in a third of patients with acute myeloid leukemia (AML), are associated with poor prognosis. Responses to currently available FLT3 inhibitors in AML patients are typically transient and followed by disease recurrence. Thus, FLT3 inhibitors with new inhibitory mechanisms are needed to improve therapeutic outcomes. AMG925 is a novel, potent, small-molecule dual inhibitor of FLT3 and CDK4/6. In this study. we determined the antileukemic effects and mechanisms of action of AMG925 in AML cell lines and primary samples, in particular AML stem/progenitor cells. AMG925 inhibited cell growth and promoted apoptosis in AML cells with or without FLT3 mutations. Reverse-phase protein array profiling confirmed its on-target effects on FLT3-CDK4/6-regulated pathways and identified unrevealed signaling network alterations in AML blasts and stem/progenitor cells in response to AMG925. Mass cytometry identified pathways that may confer resistance to AMG925 in phenotypically defined AML stem/progenitor cells and demonstrated that combined blockade of FLT3-CDK4/6 and AKT/mTOR signaling facilitated stem cell death. Our findings provide a rationale for the mechanism-based inhibition of FLT3-CDK4/6 and for combinatorial approaches to improve the efficacy of FLT3 inhibition in both FLT3 wild-type and FLT3-mutated AML. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
48. Threonine 1336 of the human insulin receptor is a major target for phosphorylation by protein kinase C
- Author
-
Czech, M [Univ. of Massachusetts Medical Center, Worcester (USA)]
- Published
- 1990
- Full Text
- View/download PDF
49. The effects of CEP-37440, an inhibitor of focal adhesion kinase, in vitro and in vivo on inflammatory breast cancer cells.
- Author
-
Salem, Israa, Alsalahi, Manal, Chervoneva, Inna, Aburto, Lucy D., Addya, Sankar, Ott, Gregory R., Ruggeri, Bruce A., Cristofanilli, Massimo, and Fernandez, Sandra V.
- Subjects
FOCAL adhesions ,CELL-matrix adhesions ,CANCER cells ,BREAST cancer research ,CANCER prognosis ,ANIMAL experimentation ,APOPTOSIS ,BENZAMIDE ,BREAST tumors ,CELL lines ,CELL physiology ,ENZYME inhibitors ,GENES ,HYDROCARBONS ,MICE ,RESEARCH funding ,TRANSFERASES - Abstract
Background: Inflammatory breast cancer (IBC) is an aggressive type of advanced breast cancer with a poor prognosis. We recently found that focal adhesion kinase 1 (FAK1) is upregulated and phosphorylated (active) in IBC. In this study, we investigated the effect of CEP-37440, a dual inhibitor of FAK1 and anaplastic lymphoma kinase (ALK), using human IBC cell lines and preclinical models of IBC.Methods: Cell proliferation assays were performed in the presence of several concentrations of CEP-37440 using IBC and triple-negative breast cancer non-IBC cell lines. In vitro, we studied the expression of total FAK1, phospho-FAK1 (Tyr 397), total ALK and phospho-ALK (Tyr 1604). In vivo, we tested CEP-37440 using FC-IBC02, SUM149, and SUM190 IBC xenograft mouse models.Results: CEP-37440 at low concentration decreased the proliferation of the IBC cell lines FC-IBC02, SUM190, and KPL4, while not affecting the proliferation of normal breast epithelial cells. At higher concentration, CEP-37440 was also able to inhibit the proliferation of the IBC cell line MDA-IBC03 and the triple-negative non-IBC cell lines MDA-MB-231 and MDA-MB-468; the IBC cell line SUM149 showed a slight response to the drug. CEP-37440 decreased the cell proliferation of FC-IBC02, SUM190, and KPL4 by blocking the autophosphorylation kinase activity of FAK1 (Tyr 397). None of the cells evaluated expressed ALK. In vivo, after 7 weeks of CEP-37440 treatment, the SUM190, FC-IBC02, and SUM149 breast tumor xenografts were smaller in mice treated with 55 mg/kg bid CEP-37440 compared to the controls; the tumor growth inhibition (TGI) was 79.7 %, 33 %, and 23 %, respectively. None of the FC-IBC02 breast xenografts mice treated with CEP-37440 developed brain metastasis while 20 % of the mice in the control group developed brain metastasis. Expression array analyses in FC-IBC02 cells showed that CEP-37440 affects the expression of genes related to apoptosis, interferon signaling, and cytokines.Conclusions: CEP-37440 is effective against some IBC cells that express phospho-FAK1 (Tyr 397), and its antiproliferative activity is related to its ability to decrease phospho-FAK1. Our results suggest that combinational therapies could be more effective than using CEP-37440 as a single agent. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
50. Activation of dsRNA-Dependent Protein Kinase R by miR-378 Sustains Metabolic Inflammation in Hepatic Insulin Resistance.
- Author
-
Wang, Hao, Song, Yongyan, Wu, Yuxin, Kumar, Virender, Mahato, Ram I., and Su, Qiaozhu
- Subjects
PROTEIN kinases ,INSULIN resistance ,RNA-binding proteins ,INSULIN sensitivity ,NON-coding RNA ,INSULIN ,HIGH-carbohydrate diet ,RNA metabolism ,BIOCHEMISTRY ,RESEARCH ,LIVER ,INFLAMMATION ,ANIMAL experimentation ,PHENOMENOLOGICAL biology ,RESEARCH methodology ,RNA ,FRUCTOSE ,EVALUATION research ,MITOCHONDRIA ,COMPARATIVE studies ,TRANSFERASES ,TUMOR necrosis factors ,RESEARCH funding ,MICE ,PHYSIOLOGY - Abstract
MicroRNAs (miRNAs) are noncoding small RNAs that regulate various pathophysiological cellular processes. Here, we report that expression of the miR-378 family was significantly induced by metabolic inflammatory inducers, a high-fructose diet, and inflammatory cytokine tumor necrosis factor-α. Hepatic miRNA profiling revealed that expression of miR-378a was highly upregulated, which, in turn, targeted the 3'-untranslated region of PPARα mRNA, impaired mitochondrial fatty acid β-oxidation, and induced mitochondrial and endoplasmic reticulum stress. More importantly, the upregulated miR-378a can directly bind to and activate the double-strand RNA (dsRNA)-dependent protein kinase R (PKR) to sustain the metabolic stress. In vivo, genetic depletion of miR-378a prevented PKR activation and ameliorated inflammatory stress and insulin resistance. Counterbalancing the upregulated miR-378a using nanoparticles encapsulated with an anti-miR-378a oligonucleotide restored PPARα activity, inhibited PKR activation and ER stress, and improved insulin sensitivity in fructose-fed mice. Our study delineated a novel mechanism of miR-378a in the pathogenesis of metabolic inflammation and insulin resistance through targeting metabolic signaling at both mRNA (e.g., PPARα) and protein (e.g., PKR) molecules. This novel finding of functional interaction between miRNAs (e.g., miR-378a) and cellular RNA binding proteins (e.g., PKR) is biologically significant because it greatly broadens the potential targets of miRNAs in cellular pathophysiological processes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.